Carien Creutzberg
Professor Radiotherapy of gynaecological tumours
- Name
- Prof.dr. C.L. Creutzberg
- Telephone
- +31 71 526 5120
- c.l.creutzberg@lumc.nl
- ORCID iD
- 0000-0002-7008-4321
Carien Creutzberg is Professor of Radiation Oncology at the Department of Radiation Oncology at Leiden University Medical Center. Her clinical, scientific and educational activities are mainly focused on improving treatment and outcome for women with gynaecological cancers. She holds several national and international scientific positions, such as member of the Advisory Board of the Dutch Cancer Society, founding member of the Dutch Gynaecological Oncology Group and senior editor of the International Journal of Gynecological Cancer.
More information about Carien Creutzberg
Carien Creutzberg is Professor of Radiation Oncology at the Department of Radiation Oncology at Leiden University Medical Center. Her clinical, scientific and educational activities are mainly focused on improving treatment and outcome for women with gynaecological cancers. She holds several national and international scientific positions, such as member of the Advisory Board of the Dutch Cancer Society, founding member of the Dutch Gynaecological Oncology Group and senior editor of the International Journal of Gynecological Cancer.
Radiation Oncology
The treatment of women with gynaecological cancer often includes a combination of surgery, radiation therapy and/or chemotherapy. Such treatment can have a profound impact on the subsequent life of survivors of gynaecological cancers, such as endometrial cancer and cervical cancer. Carien Creutzberg has conducted clinical research to improve the treatment of gynaecological cancers, reduce side effects, improve quality of life and understand the origin and individual properties of these cancers for over 25 years. She has been initiator and chief investigator of the four successive national and international PORTEC-trials on treatment of endometrial cancer, which have had impact on treatment guidelines worldwide. Resulting from these clinical studies, translational research projects have evolved in close collaboration with Prof Vincent Smit and dr Tjalling Bosse of the Department of Pathology. In national and international (TransPORTEC) collaborations joint research on molecular-genetic properties of endometrial cancer and their consequences for treatment is being conducted, to better predict the behaviour and prognosis of individual cancers, to enhance individually tailored treatment and reducing overtreatment. In addition, research into sexual rehabilitation after radiotherapy for gynaecological cancers and nurse-led coaching interventions to better help women recover after treatment is done in collaboration with dr Ter Kuile of the department of Gynaecology/Sexology. Creutzberg is the supervisor and co-supervisor of several PhD fellows at the departments of Radiotherapy, Pathology and Sexology.
Carien Creutzberg has published more than 110 articles in scientific journals and 10 chapters in textbooks. She is member of the Dutch Cancer Society Advisory Board, member of the Concilium of the Dutch Society for Radiotherapy and Oncology, founding board member of the Dutch Gynaecologic Oncology Group, co-chair of the GCIG Endometrial Cancer Committee, member of the Scientific Committee for the 2018 IGCS Congress, ESMO Faculty Member for Gynaecological Cancer, and senior editor of International Journal of Gynecological Cancer. She has been Council member of the European Society of Gynaecological Oncology until November 2017, chair of the ESGO Scientific Committee and co-chair of the ESMO-ESGO-ESTRO consensus meeting on Endometrial Cancer. In the past has Creutzberg also been Council member of the International Gynecological Cancer Society, chair of the Scientific Committee of the Dutch Society for Radiotherapy and Oncology and member of the NCI Uterine Corpus Cancer Task Force. She has been invited speaker at numerous national and international scientific meetings on Gynaecologic Oncology, Clinical Oncology and Radiation Oncology.
Academic career
Carien Creutzberg attended Medical School at Leiden University and graduated with honours in 1987. She specialised in Radiation Oncology at Erasmus University Cancer Center Rotterdam, where she completed clinical training in 1993, was appointed as consultant in Radiation Oncology from 1993 onwards, and defended her PhD thesis “Treatment verification in Radiation Oncology – Portal imaging in clinical practice” in 1998.
Carien Creutzberg was appointed as consultant and clinical researcher at the Department of Radiation Oncology at Leiden University Medical Centre in 2000, where she became full professor in 2012. The title of her inaugural speech was ‘Over leven, lijden en leiden’ (On life, suffering and leading)
Prizes and honourable appointments
Carien Creutzberg has been awarded Dutch Cancer Society Grants for all of the PORTEC trials, and related translational research projects and patient rehabilitation projects. Together with UK and Australian colleagues she has received grants from Cancer Research UK and the Australian National Health Medical Research Council for their participation in the PORTEC-3 trial and Radiotherapy Quality Assurance and improvement studies (TROG).
In 1999 she was recipient of the IGCS Award for the best oral presentation.
Professor Radiotherapy of gynaecological tumours
- Faculteit Geneeskunde
- Divisie 2
- Radiologie
- (2023), Predictive factors for toxicity after primary chemoradiation for locally advanced cervical cancer: a systematic review, International Journal of Radiation Oncology - Biology - Physics.
- Heerik, A.S.V.M. van den; Haar, N.T. ter; Vermij, L.; Jobsen, J.J.; Brinkhuis, M.; Roothaan, S.M.; Leon-Castillo, A.; Ortoft, G.; Hogdall, E.; Hogdall, C.; Wezel, T. van; Lutgens, L.C.H.W.; Haverkort, M.A.D.; Khattra, J.; McAlpine, J.N.; Creutzberg, C.L.; Smit, V.T.H.B.M.; Gilks, C.B.; Horeweg, N. & Bosse, T. (2023), QPOLE: A Quick, Simple, and Cheap Alternative for POLE Sequencing in Endometrial Cancer by Multiplex Genotyping Quantitative Polymerase Chain Reaction, JCO Global Oncology 9.
- Fremond, S.; Andani, S.; Wolf, J.B.; Dijkstra, J.; Melsbach, S.; Jobsen, J.J.; Brinkhuis, M.; Roothaan, S.; Jurgenliemk-Schulz, I.; Lutgens, L.C.H.W.; Nout, R.A.; Steen-banasik, E.M. van der; Boer, S.M. de; Powell, M.E.; Singh, N.; Mileshkin, L.R.; Mackay, H.J.; Leary, A.; Nijman, H.W.; Smit, V.T.H.B.M.; Creutzberg, C.L.; Horeweg, N.; Koelzer, V.H. & Bosse, T. (2023), Interpretable deep learning model to predict the molecular classification of endometrial cancer from haematoxylin and eosin-stained whole-slide images: a combined analysis of the PORTEC randomised trials and clinical cohorts, The Lancet Digital Health 5(2): e71-e82.
- Bosse, T.; Creutzberg, C.L.; Crosbie, E.J.; Han, K.; Horeweg, N.; Leary, A.; Kroep, J.R.; McAlpine, J.N.; Powell, M.E.; Blanc-Durand, F.; Bruyn, M. de; Church, D.N.; Koelzer, V.H.; Kommoss, S.; Singh, N.; Bardet, A.; Counsell, N.; Putter, H.; Tu, D.; Edmondson, R.; Gordon, C.; Ledermann, J.; Morice, P.; MacKay, H.; Nijman, H.; Nout, R.A.; Smit, V.T.H.B.M.; White, H.; Alexandre, J.; Boer, S.M. de; Boere, I.; Cooper, R.; Ethier, J.L.; Frenel, J.S.; McGrane, J.; Taylor, A.; Welch, S.; Westermann, A.M.; Linden, H.D. van der; Farrelly, L.; Feeney, A.; Kaya, M.; Liu, W.; Melis, A.; Ngadjeua-Tchouatieu, F.; Parulekar, W.; Verhoeven-Adema, K. & RAINBO Res Consortium (2023), Refining adjuvant treatment in endometrial cancer based on molecular features, International Journal of Gynecological Cancer 33(1): 109-117.
- Vermij, L.; Jobsen, J.J.; Leon-Castillo, A.; Brinkhuis, M.; Roothaan, S.; Powell, M.E.; Boer, S.M. de; Khaw, P.; Mileshkin, L.R.; Fyles, A.; Leary, A.; Genestie, C.; Jnrgenliemk-Schulz, I.M.; Crosbie, E.J.; Mackay, H.J.; Nijman, H.W.; Nout, R.A.; Smit, V.T.H.B.M.; Creutzberg, C.L.; Horeweg, N.; Bosse, T.; Boer, S.M. de & TransPORTEC Consortium (2023), Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry, British Journal of Cancer 128(7): 1360-1368.
- Kaya, M.; Horeweg, N.; Leary, A.; Welch, S.; Kommoss, S.; Weidner, N.; Fanfani, F.; Lorusso, D.; McGrane, J.; Gorp, T. van; Boere, I.; Westermann, A.M.; Heijns, J.B.; Putter, H.; Verhoeven-Adema, K.; Smit, V.T.H.B.M.; Creutzberg, C.L.; Bosse, T. & Kroep, J.R. (2023), The RAINBO MMRd-GREEN trial (GCIG/DGOG/ENGOT-EN142): A phase III trial on the addition of adjuvant durvalumab to radiotherapy in patients with high-risk MMRd endometrial cancer, Journal of Clinical Oncology 41(16).
- Vermij, L.; Jobsen, J.; Brinkhuis, M.; Roothaan, S.; Castillo, A.L. del; Singh, N.; Mileshkin, L.; Powell, M.; Ghatage, P.; Mclachlin, C.M.; Leary, A.; Genestie, C.; Nijman, H.; Hollema, H.; Jurgenliemk-Schulz, I.; Nout, R.; Smit, V.; Boer, S. de; Creutzberg, C.; Horeweg, N. & Bosse, T. (2022), Prognostic Relevance of FIGO Grading is Limited to NSMP Endometrial Carcinomas, Laboratory Investigation 102(SUPPL 1): 842-844.
- Vermij, L.; Jobsen, J.; Brinkhuis, M.; Roothaan, S.; Castillo, A.L. del; Singh, N.; Mileshkin, L.; Powell, M.; Ghatage, P.; Mclachlin, C.M.; Leary, A.; Genestie, C.; Nijman, H.; Hollema, H.; Jurgenliemk-Schulz, I.; Nout, R.; Smit, V.; Boer, S. de; Creutzberg, C.; Horeweg, N. & Bosse, T. (2022), Prognostic Relevance of FIGO Grading is Limited to NSMP Endometrial Carcinomas, Modern Pathology 35(SUPPL 2): 842-844.
- Heerik, A. van den; Haar, N. ter; Vermij, L.; Jobsen, J.; Brinkhuis, M.; Roothaan, S.; Leon-Castillo, A.; Ortoft, G.; Hogdall, E.; Hogdall, C.; Wezel, T. van; Lutgens, L.; Steen-Banasik, E. van der; McAlpine, J.N.; Creutzberg, C.; Smit, V.; Gilks, B.; Horeweg, N. & Bosse, T. (2022), QPOLE; a rapid, simple and cheap approach for POLE assessment in endometrial cancer by multiplex qPCR, Virchows Archiv 481(SUPPL 1): S6-S7.
- Dickhoff, L.; Kerkhof, E.M.; Pieters, B.R.; Westerveld, H.; Stalpers, L.J.; Velema, L.A.; Barten, D.L.; Andel, H.G. van; Niatsetski, Y.; Creutzberg, C.L.; Bosman, P.A. & Alderliesten, T. (2022), Automated optimization for cervix brachytherapy requires more than the EMBRACE-II planning aims.
- Wortman, B.G.; Post, C.C.B.; Powell, M.E.; Khaw, P.; Fyles, A.; D'Amico, R.; Haie-Meder, C.; Jurgenliemk-Schulz, I.M.; McCormack, M.; , V. do; Katsaros, D.; Bessette, P.; Baron, M.H.; Nout, R.A.; Whitmarsh, K.; Mileshkin, L.; Lutgens, L.C.H.W.; Kitchener, H.C.; Brooks, S.; Nijman, H.W.; Astreinidou, E.; Putter, H.; Creutzberg, C.L. & Boer, S.M. de (2022), Radiation therapy techniques and treatment-related toxicity in the PORTEC-3 trial, International Journal of Radiation Oncology - Biology - Physics 112(2): 390-399.
- Fremond, S.; Andani, S.; Wolf, J.B.; Dijkstra, J.; Jobsen, J.; Brinkhuis, M.; Roothaan, S.; Jurgenliemk-Schulz, I.; Lutgens, L.; Nout, R.; Steen-Banasik, E. van der; Boer, S. de; Powell, M.; Singh, N.; Mileshkin, L.; Mackay, H.; Leary, A.; Nijman, H.; Smit, V.; Creutzberg, C.; Horeweg, N.; Kolzer, V. & Bosse, T. (2022), AIRMEC - an Artificial Intelligence Model to Predict the Molecular Endometrial Cancer Classification from H&E Images, Laboratory Investigation 102(SUPPL 1): 746-747.
- Vermij, L.; Leon-Castillo, A.; Singh, N.; Powell, M.E.; Edmondson, R.J.; Genestie, C.; Khaw, P.; Pyman, J.; McLachlin, C.M.; Ghatage, P.; Boer, S.M. de; Nijman, H.W.; Smit, V.T.H.B.M.; Crosbie, E.J.; Leary, A.; Creutzberg, C.L.; Horeweg, N.; Bosse, T. & TransPORTEC Consortium (2022), p53 immunohistochemistry in endometrial cancer, Modern Pathology 35(10): 1475-1483.
- Fremond, S.; Andani, S.; Wolf, J.B.; Dijkstra, J.; Jobsen, J.; Brinkhuis, M.; Roothaan, S.; Jurgenliemk-Schulz, I.; Lutgens, L.; Nout, R.; Steen-Banasik, E. van der; Boer, S. de; Powell, M.; Singh, N.; Mileshkin, L.; Mackay, H.; Leary, A.; Nijman, H.; Smit, V.; Creutzberg, C.; Horeweg, N.; Kolzer, V. & Bosse, T. (2022), AIRMEC - an Artificial Intelligence Model to Predict the Molecular Endometrial Cancer Classification from H&E Images, Modern Pathology 35(SUPPL 2): 746-747.
- Dickhoff LRM, Kerkhof EM, Deuzeman HH, Creutzberg CL, Alderliesten T & Bosman PAN. (2022), Adaptive Objective Configuration in Bi-Objective Evolutionary Optimization for Cervical Cancer Brachytherapy Treatment Planning.
- Khaw, P.; , V. do; Lim, K.; Cunninghame, J.; Dixon, J.; Vassie, J.; Bailey, M.; Johnson, C.; Kahl, K.; Gordon, C.; Cook, O.; Foo, K.; Fyles, A.; Powell, M.; Haie-Meder, C.; D'Amico, R.; Bessette, P.; Mileshkin, L.; Creutzberg, C.L. & Moore, A. (2022), Radiotherapy quality assurance in the PORTEC-3 (TROG 08.04) trial, Clinical Oncology 34(3): 198-204.
- Wu, J.Q.; Horeweg, N.; Bruyn, M. de; Nout, R.A.; Jurgenliemk-Schulz, I.M.; Lutgens, L.C.H.W.; Jobsen, J.J.; Steen-Banasik, E.M. van der; Nijman, H.W.; Smit, V.T.H.B.M.; Bosse, T.; Creutzberg, C.L. & Koelzer, V.H. (2022), Automated causal inference in application to randomized controlled clinical trials, Nature Machine Intelligence 4(5): 436-+.
- Leon-Castillo, A.; Horeweg, N.; Peters, E.E.M.; Rutten, T.; Haar, N. ter; Smit, V.T.H.B.M.; Kroon, C.D.; Boennelycke, M.; Hogdall, E.; Hogdall, C.; Nout, R.R.A.; Creutzberg, C.L.; Ortoft, G. & Bosse, T. (2022), Prognostic relevance of the molecular classification in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatment, Gynecologic Oncology 164(3).
- Dickhoff, L.; Kerkhof, E.M.; Pieters, B.R.; Westerveld, H.; Stalpers, L.J.; Velema, L.A.; Barten, D.L.; Andel, H.G. van; Niatsetski, Y.; Creutzberg, C.L.; Bosman, P.A. & Alderliesten, T. (2022), Automated optimization for cervix brachytherapy requires more than the EMBRACE-II planning aims, Radiotherapy & Oncology 170: S388-S390.
- Lisa Vermij, Jan J. Jobsen, Alicia León-Castillo, Mariel Brinkhuis, Suzan Roothaan, Melanie E. Powell, Stephanie M. de Boer, Pearly Khaw, Linda R. Mileshkin, Anthony Fyles, Alexandra Leary, Catherine Genestie, Ina M. Jürgenliemk-Schulz, Emma J. Crosbie, Helen J. Mackay,Hans. W. Nijman, Remi A. Nout, Vincent T.H.B.M. Smit, Carien L. Creutzberg, Nanda Horeweg, Tjalling Bosse & TransPORTEC consortium (2022), Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry.
- Gaffney, D.; Creutzberg, C.L. & Jhingran, A. (2022), Special Issue: Radiation Oncology in Gynecologic Malignancies., International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.
- Luyten, G.P.M.; Shirzada, M.R.; Marinkovic, M.; Vught, L. van; Beenakker, J.W.M.; Bleeker, J.; Creutzberg, C. & Vu, T.H.K. (2022), Is regression rate in choroidal melanomas treated with Ruthenium-106 brachytherapy associated with the risk for metastatic disease?, Acta Ophthalmologica 100: 42-43.
- Heerik, A.S.V.M.V.; Aiyer, K.T.S.; Stelloo, E.; Juergenliemk-Schulz, I.M.; Lutgens, L.C.H.W.; Jobsen, J.J.; Mens, J.W.M.; Steen-banasik, E.M. van der; Creutzberg, C.L.; Smit, V.T.H.B.M.; Horeweg, N. & Bosse, T. (2022), Microcystic elongated and fragmented (MELF) pattern of invasion, Gynecologic Oncology 166(3): 530--537.
- Heerik, A.S.V.M. van den; Horeweg, N.; Creutzberg, C.L. & Nout, R.A. (2022), Vaginal brachytherapy management of stage I and II endometrial cancer, International Journal of Gynecological Cancer.
- Horeweg, N.; Workel, H.H.; Loiero, D.; Church, D.N.; Vermij, L.; Leon-Castillo, A.; Krog, R.T.; Boer, S.M. de; Nout, R.A.; Powell, M.E.; Mileshkin, L.R.; MacKay, H.; Leary, A.; Singh, N.; Jurgenliemk-Schulz, I.M.; Smit, V.T.H.B.M.; Creutzberg, C.L.; Koelzer, V.H.; Nijman, H.W.; Bosse, T. & Bruyn, M. de (2022), Tertiary lymphoid structures critical for prognosis in endometrial cancer patients, Nature Communications 13(1).
- Jamieson, A.; Vermij, L.; Carlson, J.; Howitt, B.; Ip, P.; Lax, S.; Mccluggage, G.; Singh, N.; Mcalpine, J.; Nout, R.; Creutzberg, C.; Gilks, B.; Horeweg, N. & Bosse, T. (2022), LOW-GRADE P53ABN ENDOMETRIAL CARCINOMAS EXIST AND ARE ASSOCIATED WITH A HIGH RISK OF RECURRENCE, EVEN IN LOW-STAGE DISEASE, International Journal of Gynecological Cancer 32: A94-A95.
- Peters, E.; Leon-Castillo, A.; Smit, V.; Boennelycke, M.; Hogdall, E.; Hogdall, C.; Creutzberg, C.; Jurgenliemk-Schulz, I.; Jobsen, J.; Mens, J.W.; Lutgens, L.; Steen-Banasik, E. van der; Ortoft, G.; Bosse, T. & Nout, R. (2021), Defining Substantial Lymphovascular Space Invasion in Endometrial Cancer, Modern Pathology 34(SUPPL 2): 729-730.
- Oonk, M.H.M.; Slomovitz, B.; Baldwin, P.J.W.; Doorn, H.C. van; Velden, J. van der; Hullu, J.A. de; Gaarenstroom, K.N.; Slangen, B.F.M.; Vergote, I.; Brannstrom, M.; Dorst, E.B.L. van; Driel, W.J. van; Hermans, R.H.; Nunns, D.; Widschwendter, M.; Nugent, D.; Holland, C.M.; Sharma, A.; DiSilvestro, P.A.; Mannel, R.; Boll, D.; Cibula, D.; Covens, A.; Provencher, D.; Runnebaum, I.B.; Luesley, D.; Ellis, P.; Duncan, T.J.; Tjiong, M.Y.; Cruickshank, D.J.; Kjolhede, P.; Levenback, C.F.; Bouda, J.; Kieser, K.E.; Palle, C.; Spirtos, N.M.; O'Malley, D.M.; Leitao, M.M.; Geller, M.A.; Dhar, K.; Asher, V.; Tamussino, K.; Tobias, D.H.; Borgfeldt, C.; Lea, J.S.; Bailey, J.; Lood, M.; Eyjolfsdottir, B.; Attard-Montalto, S.; Tewari, K.S.; Manchanda, R.; Jensen, P.T.; Persson, P.; , L. van le; Putter, H.; Bock, G.H. de; Monk, B.J.; Creutzberg, C.L. & Zee, A.G.J. van der (2021), Radiotherapy versus inguinofemoral lymphadenectomy as treatment for vulvar cancer patients with micrometastases in the sentinel node, Journal of Clinical Oncology 39(32): 3623-+.
- N H, H W, D L, D C, L V, A L, R K, de Boer S, R N, M P, L M, H M, A L, N S & M B (2021), Tertiary lymphoid structures critical for prognosis in endometrial cancer patients - a TransPORTEC study.
- Horeweg, N.; Workel, H.; Loiero, D.; Church, D.; Vermij, L.; Leon-Castillo, A.; Boer, S. de; Nout, R.; Powell, M.; Mileshkin, L.; Mackay, H.; Leary, A.; Singh, N.; Jurgenliemk-Schulz, I.; Creutzberg, C.L.; Kolzer, V.; Nijman, H.W.; Bosse, T. & Bruyn, M. de (2021), Tertiary lymphoid structures as markers of anti-tumor immunity with independent prognostic value in the PORTEC-3 trial of high-risk endometrial cancer, International Journal of Gynecological Cancer 31: A99-A101.
- Leon-Castillo, A.; Horeweg, N.; Peters, E.; Rutten, T.; Haar, N. ter; Smit, V.; Boennelycke, M.; Hogdall, E.; Hogdall, C.; Nout, R.; Creutzberg, C.L.; Ortoft, G. & Bosse, T. (2021), Prognostic relevance of the molecular endometrial cancer classification among patients staged by lymphadenectomy and/or without adjuvant treatment, International Journal of Gynecological Cancer 31: A90-A91.
- Heerik, A.S. van den; Haar, N. ter; Horeweg, N.; Wezel, T. van; Creutzberg, C.; Smit, V. & Bosse, T. (2021), Multiplex QPCR hotspot testing of pathogenic POLE mutations: a rapid, simple, and reliable approach for POLE assessment in endometrial cancer, International Journal of Gynecological Cancer 31: A367-A368.
- Bosse, T.; Powell, M.; Crosbie, E.; Leary, A.; Kroep, J.; Han, K.; Mcalpine, J.; Horeweg, N.; Boer, S. de; Bruyn, M. de; Nout, R.; Smit, V.; Nijman, H.W.; Singh, N.; Mackay, H.; Edmondson, R.; Mileshkin, L.; Church, D.; Kitchener, H. & Creutzberg, C.L. (2021), Implementation of collaborative translational research (TRANSPORTEC) findings in an international endometrial cancer clinical trials program (RAINBO), International Journal of Gynecological Cancer 31: A108-A109.
- Vermij, L.; Powell, M.; Leon-Castillo, A.; Boer, S. de; Mileshkin, L.; Mackay, H.; Leary, A.; Nijman, H.W.; Singh, N.; Pollock, P.; Bessette, P.; Haie-Meder, C.; Smit, V.; Edmondson, R.; Crosbie, E.; Nout, R.; Horeweg, N.; Creutzberg, C.L. & Bosse, T. (2021), Molecular profiling of NSMP high-risk endometrial cancers of the PORTEC-3 trial - prognostic refinement and druggable targets, International Journal of Gynecological Cancer 31: A89-A90.
- Heerik, A.S. van den; Aiyer, K.; Jurgenliemk-Schulz, I.; Jobsen, J.; Mens, J.W.; Lutgens, L.; Nout, R.; Creutzberg, C.L.; Smit, V.; Horeweg, N. & Bosse, T. (2021), Molecular features and prognostic impact of MELF type myometrial invasion in the PORTEC-1/2 cohort of early stage endometrial cancers, International Journal of Gynecological Cancer 31: A107-A108.
- Heerik, A.S.V.M. van den; Horeweg, N.; Boer, S.M. de; Bosse, T. & Creutzberg, C.L. (2021), Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy, International Journal of Gynecological Cancer 31(4): 594-604.
- Wortman, B.; Post, C.; Powell, M.; Khaw, P.; Fyles, A.; D'Amico, R.; Haie-Meder, C.; Jurgenliemk-Schulz, I.; McCormack, M.; , V. do; Katsaros, D.; Bessette, P.; Baron, M.; Nout, R.; Whitmarsh, K.; Mileshkin, L.; Lutgens, L.; Kitchener, H.; Brooks, S.; Nijman, H.; Astreinidou, E.; Putter, H.; Creutzberg, C. & Boer, S. de (2021), Toxicity and patient-reported symptoms after 3D-conformal or intensity-modulated pelvic radiotherapy, Radiotherapy & Oncology 161: S204-S205.
- Post, C.C.B.; Boer, S.M. de; Powell, M.E.; Mileshkin, L.; Katsaros, D.; Bessette, P.; Haie-Meder, C.; Ottevanger, N.P.B.; Ledermann, J.A.; Khaw, P.; D'Amico, R.; Fyles, A.; Baron, M.H.; Kitchener, H.C.; Nijman, H.W.; Lutgens, L.C.H.W.; Brooks, S.; Jurgenliemk-Schulz, I.M.; Feeney, A.; Goss, G.; Fossati, R.; Ghatage, P.; Leary, A.; , V. do; Lissoni, A.A.; McCormack, M.; Nout, R.A.; Verhoeven-Adema, K.W.; Smit, V.T.H.B.M.; Putter, H. & Creutzberg, C.L. (2021), Long-term toxicity and health-related quality of life after adjuvant chemoradiation therapy or radiation therapy alone for high-risk endometrial cancer in the randomized PORTEC-3 trial, International Journal of Radiation Oncology - Biology - Physics 109(4): 975-986.
- Cathalijne Post, , Ellen Stelloo, , Vincent Smit, , Dina Ruano, , Carli Tops, , Lisa Vermij, , Tessa Rutten, , Ina Jurgenliemk-Schulz, , Ludy Lutgens, , Jan Jobsen, , Remi Nout, , Emma Crosbie, , Alexandra Leary, , Linda Mileshkin, , Stephanie Boer, de , Nanda Horeweg, , Tom Wezel, van , Carien Creutzberg, , Tjalling Bosse & (2021), Unmethylated Mismatch Repair Deficiency in the Combined PORTEC-1,-2 and-3 Endometrial Cancer Trials: Underlying Causes and Survival Analysis.
- Greimel, E.; Nagele, E.; Lanceley, A.; Oberguggenberger, A.S.; Nordin, A.; Kuljanic, K.; Arraras, J.I.; Chie, W.C.; Jensen, P.T.; Tomaszewski, K.A.; Creutzberg, C.L.; Galalae, R.; Toelen, H.; Zimmermann, K.; Bjelic-Radisic, V.; Costantini, A.; Almont, T.; Serpentini, S.; Froding, L.P.; Vistad, I.; Schmalz, C. & EORTC Quality Life Grp (2021), Psychometric validation of the European Organisation for Research and Treatment of Cancer-Quality of Life Questionnaire Sexual Health (EORTC QLQ-SH22), European Journal of Cancer 154: 235-245.
- Concin, N.; Matias-Guiu, X.; Creutzberg, C.L. & ESGO-ESTRO-ESP Endometrial (2021), Response to: Are we confident treating pT1a G1 lymphovascular space invasion-negative patients (with myometrial invasion) with chemoradiotherapy on the basis of p53abn?
- Leon-Castillo, A.; Vermij, L.; Boer, S. de; Singh, N.; Fyles, A.; Mclachlin, C.M.; Leary, A.; Nijman, H.; Smit, V.; Nout, R.; Horeweg, N.; Creutzberg, C. & Bosse, T. (2021), Performance of p53 Immunohistochemistry as a Surrogate Marker for TP53 Mutations in the PORTEC-3 Endometrial Carcinoma Cohort, Modern Pathology 34(SUPPL 2): 710-711.
- Corbeau, A.; Nout, R.A.; Mens, J.W.M.; Horeweg, N.; Godart, J.; Kerkhof, E.M.; Kuipers, S.C.; Poelgeest, M.I.E. van; Kroep, J.R.; Boere, I.A.; Doorn, H.C. van; Hoogeman, M.S.; Heide, U.A. van der; Putter, H.; Welters, M.J.P.; Burg, S.H. van der; Creutzberg, C.L. & Boer, S.M. de (2021), PROTECT: prospective phase-II-trial evaluating adaptive proton therapy for cervical cancer to reduce the impact on morbidity and the immune system, Cancers 13(20).
- Triest, B. van; Rasing, M.; Velden, J. van der; Hullu, J. de; Witteveen, P.O.; Beukema, J.C.; Steen-Banasik, E. van der; Westerveld, H.; Snyers, A.; Peters, M.; Creutzberg, C.L.; Nout, R.A.; Lutgens, L. & Jurgenliemk-Schulz, I. (2021), Phase II study of definitive chemoradiation for locally advanced squamous cell cancer of the vulva: An efficacy study, Gynecologic Oncology 163(1): 117-124.
- Post, C.C.B.; Mens, J.W.M.; Haverkort, M.A.D.; Koppe, F.; Jürgenliemk-Schulz, I.M.; Snyers, A.; Roeloffzen, E.M.A.; Schaake, E.E.; Slot, A.; Stam, T.C.; Beukema, J.C.; Berg, H.A. van den; Lutgens, L.C.H.W.; Nijman, H.W.; Kroon, C.D. de; Kroep, J.R.; Stiggelbout, A.M. & Creutzberg, C.L. (2021), Patients' and clinicians' preferences in adjuvant treatment for high-risk endometrial cancer: Implications for shared decision making., Gynecologic Oncology.
- Koskas, M.; Amant, F.; Mirza, M.R. & Creutzberg, C.L. (2021), Cancer of the corpus uteri: 2021 update, International Journal of Gynecology & Obstetrics 155: 45-60.
- Suvaal, I.; Hummel, S.B.; Mens, J.W.M.; Doorn, H.C. van; Hout, W.B. van den; Creutzberg, C.L. & Kuile, M.M. ter (2021), A sexual rehabilitation intervention for women with gynaecological cancer receiving radiotherapy (SPARC study), BMC Cancer 21(1).
- Post, C.; Stelloo, E.; Smit, V.; Ruano, D.; Tops, C.; Vermij, L.; Rutten, T.; Jurgenliemk-Schulz, I.; Lutgens, L.; Jobsen, J.; Nout, R.; Crosbie, E.; Leary, A.; Mileshkin, L.; Boer, S. de; Horeweg, N.; Wezel, T. van; Creutzberg, C. & Bosse, T. (2021), Unmethylated Mismatch Repair Deficiency in the Combined PORTEC-1,-2 and-3 Endometrial Cancer Trials: Underlying Causes and Survival Analysis, Laboratory Investigation 101(SUPPL 1): 733-734.
- Wortman, B.G.; Post, C.C.B.; Powell, M.E.; Khaw, P.; Fyles, A.; D'Amico, R.; Haie-Meder, C.; Jürgenliemk-Schulz, I.M.; McCormack, M.; , V. do; Katsaros, D.; Bessette, P.; Baron, M.H.; Nout, R.A.; Whitmarsh, K.; Mileshkin, L.; Lutgens, L.C.H.W.; Kitchener, H.C.; Brooks, S.; Nijman, H.W.; Astreinidou, E.; Putter, H.; Creutzberg, C.L. & Boer, S.M. de (2021), Radiation Therapy Techniques and Treatment-Related Toxicity in the PORTEC-3 Trial: Comparison of 3-Dimensional Conformal Radiation Therapy Versus Intensity-Modulated Radiation Therapy., International journal of radiation oncology, biology, physics.
- Wortman, B.G.; Astreinidou, E.; Laman, M.S.; Steen-Banasik, E.M. van der; Lutgens, L.C.H.W.; Westerveld, H.; Koppe, F.; Slot, A.; Berg, H.A. van den; Nowee, M.E.; Bijmolt, S.; Stam, T.C.; Zwanenburg, A.G.; Mens, J.W.M.; Jurgenliemk-Schulz, I.M.; Snyers, A.; Gillham, C.M.; Weidner, N.; Kommoss, S.; Vandecasteele, K.; Tomancova, V.; Creutzberg, C.L.; Nout, R.A. & PORTEC Study Grp (2021), Brachytherapy quality assurance in the PORTEC-4a trial for molecular-integrated risk profile guided adjuvant treatment of endometrial cancer, Radiotherapy & Oncology 155: 160--166.
- Post, C.; Stelloo, E.; Smit, V.; Ruano, D.; Tops, C.; Vermij, L.; Rutten, T.; Jurgenliemk-Schulz, I.; Lutgens, L.; Jobsen, J.; Nout, R.; Crosbie, E.; Leary, A.; Mileshkin, L.; Boer, S. de; Horeweg, N.; Wezel, T. van; Creutzberg, C. & Bosse, T. (2021), Unmethylated Mismatch Repair Deficiency in the Combined PORTEC-1,-2 and-3 Endometrial Cancer Trials: Underlying Causes and Survival Analysis, Modern Pathology 34(SUPPL 2): 733-734.
- Peters, E.E.M.; Léon-Castillo, A.; Hogdall, E.; Boennelycke, M.; Smit, V.T.H.B.M.; Hogdall, C.; Creutzberg, C.L.; Bosse, T.; Nout, R.A. & Ortoft, G. (2021), Substantial Lymphovascular Space Invasion Is an Adverse Prognostic Factor in High-risk Endometrial Cancer., International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
- Peters, E.; Leon-Castillo, A.; Smit, V.; Boennelycke, M.; Hogdall, E.; Hogdall, C.; Creutzberg, C.; Jurgenliemk-Schulz, I.; Jobsen, J.; Mens, J.W.; Lutgens, L.; Steen-Banasik, E. van der; Ortoft, G.; Bosse, T. & Nout, R. (2021), Defining Substantial Lymphovascular Space Invasion in Endometrial Cancer, Laboratory Investigation 101(SUPPL 1): 729-730.
- Leon-Castillo, A.; Vermij, L.; Boer, S. de; Singh, N.; Fyles, A.; Mclachlin, C.M.; Leary, A.; Nijman, H.; Smit, V.; Nout, R.; Horeweg, N.; Creutzberg, C. & Bosse, T. (2021), Performance of p53 Immunohistochemistry as a Surrogate Marker for TP53 Mutations in the PORTEC-3 Endometrial Carcinoma Cohort, Laboratory Investigation 101(SUPPL 1): 710-711.
- Concin, N.; Matias-Guiu, X.; Vergote, I.; Cibula, D.; Mirza, M.R.; Marnitz, S.; Ledermann, J.; Bosse, T.; Chargari, C.; Fagotti, A.; Fotopoulou, C.; Martin, A.G.; Lax, S.; Lorusso, D.; Marth, C.; Morice, P.; Nout, R.A.; O'Donnell, D.; Querleu, D.; Raspollini, M.R.; Sehouli, J.; Sturdza, A.; Taylor, A.; Westermann, A.; Wimberger, P.; Colombo, N.; Planchamp, F. & Creutzberg, C.L. (2021), ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 154.
- Concin, N.; Creutzberg, C.L.; Vergote, I.; Cibula, D.; Mirza, M.R.; Marnitz, S.; Ledermann, J.A.; Bosse, T.; Chargari, C.; Fagotti, A.; Fotopoulou, C.; Gonzalez-Martin, A.; Lax, S.F.; Lorusso, D.; Marth, C.; Morice, P.; Nout, R.A.; O'Donnell, D.E.; Querleu, D.; Raspollini, M.R.; Sehouli, J.; Sturdza, A.E.; Taylor, A.; Westermann, A.M.; Wimberger, P.; Colombo, N.; Planchamp, F. & Matias-Guiu, X. (2021), ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma., Virchows Archiv : an international journal of pathology 478.
- Westerveld, H.; Schmid, M.P.; Nout, R.A.; Chargari, C.; Pieters, B.R.; Creutzberg, C.L.; Sturdza, A.; Lindegaard, J.C.; Kesteren, Z. van; Mazeron, R.; Nesvacil, N. & Fokdal, L.U. (2021), Image-guided adaptive brachytherapy (IGABT) for primary vaginal cancer, Cancers 13(6).
- Post, C.C.B.; Mens, J.W.M.; Haverkort, M.A.D.; Koppe, F.; Jurgenliemk-Schulz, I.M.; Snyers, A.; Roeloffzen, E.M.A.; Schaake, E.E.; Slot, A.; Stam, T.C.; Beukema, J.C.; Berg, H.A. van den; Lutgens, L.C.H.W.; Nijman, H.W.; Kroon, C.D. de; Kroep, J.R.; Stiggelbout, A.M. & Creutzberg, C.L. (2021), Patients' and clinicians' preferences in adjuvant treatment for high-risk endometrial cancer, Gynecologic Oncology 161(3).
- Post, C.; Stelloo, E.; Smit, V.; Ruano, D.; Tops, C.M.; Vermij, L.; Rutten, T.A.; Jurgenliemk-Schulz, I.M.; Lutgens, L.C.; Jobsen, J.J.; Nout, R.A.; Crosbie, E.J.; Powell, M.E.; Mileshkin, L.; Leary, A.; Bessette, P.; Boer, S.M. de; Horeweg, N.; Wezel, T. van; Bosse, T. & Creutzberg, C.L. (2021), Prevalence and prognosis of Lynch syndrome and sporadic mismatch repair deficiency in endometrial cancer, Journal of the National Cancer Institute 113(9).
- Zayed, S.; Nguyen, T.K.; Lin, C.; Boldt, G.; Beriwal, S.; Creutzberg, C.L.; Kamrava, M.; Mendez, L.C.; Velker, V.; Doll, C.; Taggar, A.; Leung, E. & D'Souza, D.P. (2021), Red blood cell transfusion practices for patients with cervical cancer undergoing radiotherapy, Jama Network Open 4(4).
- Akker, M.J.E. van den; Horeweg, N.; Beltman, J.J.; Creutzberg, C.L. & Nout, R.A. (2020), Efficacy and toxicity of postoperative external beam radiotherapy or chemoradiation for early-stage cervical cancer., International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.
- Heerik, A.S.V.M. van den; Horeweg, N.; Boer, S.M. de; Bosse, T. & Creutzberg, C.L. (2020), Adjuvant therapy for endometrial cancer in the era of molecular classification, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2021(34).
- Creutzberg, E.C.; Wijngaard-Boom, P.; Stijnen, T. & Laven, J. (2020), The use of follitropin delta for ovarian stimulation for in vitro fertilization in patients with a low ovarian reserve: results from clinical practice, Human Reproduction 35: 1452-1452.
- Laven, J.; Wijngaard-Boom, P.; Stijnen, T. & Creutzberg, E. (2020), The use of follitropin delta for ovarian stimulation for in vitro fertilization in patients with anovulatory PCOS: results in clinical practice, Human Reproduction 35: 1455-1456.
- Post, C.; Stelloo, E.; Smit, V.; Ruano, D.; Tops, C.M.; Vermij, L.; Rutten, T.A.; Jurgenliemk-Schulz, I.M.; Lutgens, L.C.; Jobsen, J.J.; Nout, R.A.; Crosbie, E.J.; Powell, M.E.; Mileshkin, L.; Leary, A.; Bessette, P.; Boer, S.M. de; Horeweg, N.; Wezel, T. van; Bosse, T. & Creutzberg, C.L. (2020), Prevalence and prognosis of Lynch syndrome and sporadic mismatch repair deficiency in the combined portec-1,-2, and -3 endometrial cancer trials, International Journal of Gynecological Cancer.
- Vermij, L.; Horeweg, N.; Leon-Castillo, A.; Rutten, T.A.; Mileshkin, L.R.; Mackay, H.J.; Leary, A.; Powell, M.E.; Singh, N.; Crosbie, E.J.; Smit, V.T.H.B.M.; Creutzberg, C.L. & Bosse, T. (2020), HER2 Status in High-Risk Endometrial Cancers (PORTEC-3): Relationship with Histotype, Molecular Classification, and Clinical Outcomes., Cancers.
- Wijngaard-Boom, P.; Creutzberg, E.; Stijnen, T. & Laven, J.S.E. (2020), Individualised follitropin delta dosing for ovarian stimulation in daily practice in a Dutch IVF centre, Human Reproduction 35: 1454-1454.
- Post, C.; Boer, S.M. de; Powell, M.E.; Mileshkin, L.; Katsaros, D.; Bessette, P.; Haie-Meder, C.; Ottevanger, P.B.; Ledermann, J.A.; Khaw, P.; D'Amico, R.; Fyles, A.; Baron, M.; Kitchener, H.C.; Nijman, H.W.; Lutgens, L.C.; Brooks, S.; Jurgenliemk-Schulz, I.M.; Feeney, A.; Nout, R.A.; Verhoeven-Adema, K.W.; Smit, V.T.; Putter, H. & Creutzberg, C.L. (2020), Long-Term Quality of Life after (chemo)radiotherapy for high-risk Endometrial Cancer in PORTEC-3, Radiotherapy & Oncology 152: S199-S200.
- Heerik, A.S.V.M. van den; Horeweg, N.; Nout, R.A.; Lutgens, L.C.H.W.; Steen-banasik, E.M. van der; Westerveld, G.H.; Berg, H.A. van den; Slot, A.; Koppe, F.L.A.; Kommoss, S.; Mens, J.W.M.; Nowee, M.E.; Bijmolt, S.; Cibula, D.; Stam, T.C.; Jurgenliemk-Schulz, I.M.; Snyers, A.; Hamann, M.; Zwanenburg, A.G.; Coen, V.L.M.A.; Vandecasteele, K.; Gillham, C.; Chargari, C.; Verhoeven-Adema, K.W.; Putter, H.; Hout, W.B. van den; Wortman, B.G.; Nijman, H.W.; Bosse, T. & Creutzberg, C.L. (2020), PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer., International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.
- León-Castillo, A.; Boer, S.M. de; Powell, M.E.; Mileshkin, L.R.; Mackay, H.J.; Leary, A.; Nijman, H.W.; Singh, N.; Pollock, P.M.; Bessette, P.; Fyles, A.; Haie-Meder, C.; Smit, V.T.H.B.M.; Edmondson, R.J.; Putter, H.; Kitchener, H.C.; Crosbie, E.J.; Bruyn, M. de; Nout, R.A.; Horeweg, N.; Creutzberg, C.L.; Bosse, T. & TransPORTEC Consortium (2020), Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy., Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
- Concin, N.; Matias-Guiu, X.; Vergote, I.; Cibula, D.; Mirza, M.R.; Marnitz, S.; Ledermann, J.; Bosse, T.; Chargari, C.; Fagotti, A.; Fotopoulou, C.; Martin, A.G.; Lax, S.; Lorusso, D.; Marth, C.; Morice, P.; Nout, R.A.; O'Donnell, D.; Querleu, D.; Raspollini, M.R.; Sehouli, J.; Sturdza, A.; Taylor, A.; Westermann, A.; Wimberger, P.; Colombo, N.; Planchamp, F. & Creutzberg, C.L. (2020), ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma., International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2021(31).
- Marinkovic, M.; Vu, K.; Bleeker, J.; Creutzberg, C.; Rasch, C. & Luijten, G. (2020), Proton beam irradiation in the Netherlands; the Leiden experience, Acta Ophthalmologica 98: 15-15.
- Post, C.C.B.; Westermann, A.M.; Bosse, T.; Creutzberg, C.L. & Kroep, J.R. (2020), PARP and PD-1/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer, Critical Reviews in Oncology/Hematology 152.
- Leon-Castillo, A.; Boer, S.M. de; Powell, M.E.; Mileshkin, L.R.; Mackay, H.J.; Leary, A.; Nijman, H.W.; Singh, N.; Pollock, P.M.; Bessette, P.; Fyles, A.; Haie-Meder, C.; Smit, V.T.H.B.M.; Edmondson, R.J.; Putter, H.; Kitchener, H.C.; Crosbie, E.J.; Bruyn, M. de; Nout, R.A.; Horeweg, N.; Creutzberg, C.L.; Bosse, T. & TransPORTEC Consortium (2020), Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer, Journal of Clinical Oncology 38(29): 3388-+.
- Sessa, C.; Colombo, N.; Creutzberg, C.L.; Concin, N.; Wimberger, P.; Marinoni, K.A.; Douillard, J.Y.; Torri, V. & Rauh, S. (2020), Limited implementation of the ESMO-ESGO (European Society of Gynaecological Oncology)-ESTRO (European Society for Radiotherapy and Oncology) consensus conference recommendations (CCR) on endometrial cancer (EC), Annals of Oncology 31(4): S638-S638.
- Wortman, B.G.; Astreinidou, E.; Laman, M.S.; Steen-Banasik, E.M. van der; Lutgens, L.C.H.W.; Westerveld, H.; Koppe, F.; Slot, A.; Berg, H.A. van den; Nowee, M.E.; Bijmolt, S.; Stam, T.C.; Zwanenburg, A.G.; Mens, J.W.M.; Jurgenliemk-Schulz, I.M.; Snyers, A.; Gillham, C.M.; Weidner, N.; Kommoss, S.; Vandecasteele, K.; Tomancova, V.; Creutzberg, C.L.; Nout, R.A. & PORTEC Study Grp (2020), Brachytherapy quality assurance in the PORTEC-4a trial for molecular-integrated risk profile guided adjuvant treatment of endometrial cancer., Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 155.
- Post, C.C.B.; Boer, S.M. de; Powell, M.E.; Mileshkin, L.; Katsaros, D.; Bessette, P.; Haie-Meder, C.; Ottevanger, N.P.B.; Ledermann, J.A.; Khaw, P.; D'Amico, R.; Fyles, A.; Baron, M.H.; Kitchener, H.C.; Nijman, H.W.; Lutgens, L.C.H.W.; Brooks, S.; Jurgenliemk-Schulz, I.M.; Feeney, A.; Goss, G.; Fossati, R.; Ghatage, P.; Leary, A.; , V. do; Lissoni, A.A.; McCormack, M.; Nout, R.A.; Verhoeven-Adema, K.W.; Smit, V.T.H.B.M.; Putter, H. & Creutzberg, C.L. (2020), Long-term toxicity and health-related quality of life after adjuvant chemoradiation therapy or radiation therapy alone for high-risk endometrial cancer in the randomized PORTEC-3 trial., International journal of radiation oncology, biology, physics 109(4).
- Small, W.; Bosch, W.R.; Harkenrider, M.M.; Strauss, J.B.; Abu-Rustum, N.; Albuquerque, K.V.; Beriwal, S.; Creutzberg, C.L.; Eifel, P.J.; Erickson, B.A.; Fyles, A.W.; Hentz, C.L.; Jhingran, A.; Klopp, A.H.; Kunos, C.A.; Mell, L.K.; Portelance, L.; Powell, M.E.; Viswanathan, A.N.; Yacoub, J.H.; Yashar, C.M.; Winter, K.A. & Gaffney, D.K. (2020), NRG oncology/RTOG consensus guidelines for delineation of clinical target volume for intensity modulated pelvic radiation therapy in postoperative treatment of endometrial and cervical cancer, International journal of radiation oncology, biology, physics 109(2).
- Akker, M.J.E. van den; Horeweg, N.; Beltman, J.J.; Creutzberg, C.L. & Nout, R.A. (2020), Efficacy and toxicity of postoperative external beam radiotherapy or chemoradiation for early-stage cervical cancer, International Journal of Gynecological Cancer 30(12): 1878-1886.
- Vermij, L.; Horeweg, N.; Leon-Castillo, A.; Rutten, T.A.; Mileshkin, L.R.; Mackay, H.J.; Leary, A.; Powell, M.E.; Singh, N.; Crosbie, E.J.; Smit, V.T.H.B.M.; Creutzberg, C.L. & Bosse, T. (2020), HER2 status in high-risk endometrial cancers (PORTEC-3), Cancers 2021(1).
- Heerik, A.S.V.M. van den; Horeweg, N.; Nout, R.A.; Lutgens, L.C.H.W.; Steen-banasik, E.M. van der; Westerveld, G.H.; Berg, H.A. van den; Slot, A.; Koppe, F.L.A.; Kommoss, S.; Mens, J.W.M.; Nowee, M.E.; Bijmolt, S.; Cibula, D.; Stam, T.C.; Jurgenliemk-Schulz, I.M.; Snyers, A.; Hamann, M.; Zwanenburg, A.G.; Coen, V.L.M.A.; Vandecasteele, K.; Gillham, C.; Chargari, C.; Verhoeven-Adema, K.W.; Putter, H.; Hout, W.B. van den; Wortman, B.G.; Nijman, H.W.; Bosse, T. & Creutzberg, C.L. (2020), PORTEC-4a, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2020(30).
- Post, C.; Stelloo, E.; Smit, V.; Ruano, D.; Tops, C.M.; Vermij, L.; Rutten, T.A.; Jurgenliemk-Schulz, I.M.; Lutgens, L.C.; Jobsen, J.J.; Nout, R.A.; Crosbie, E.J.; Powell, M.E.; Mileshkin, L.; Leary, A.; Bessette, P.; Boer, S.M. de; Horeweg, N.; Wezel, T. van; Bosse, T. & Creutzberg, C.L. (2020), Prevalence and prognosis of Lynch syndrome and sporadic mismatch repair deficiency in the combined portec-1,-2 and-3 endometrial cancer trials, International Journal of Gynecological Cancer 30: A20-A20.
- Horeweg, N.; Bruyn, M. de; Nout, R.A.; Stelloo, E.; Kedziersza, K.; Leon-Castillo, A.; Plat, A.; Mertz, K.D.; Osse, M.; Jurgenliemk-Schulz, I.M.; Lutgens, L.C.H.W.; Jobsen, J.J.; Steen-Banasik, E.M. van der; Smit, V.T.; Creutzberg, C.L.; Bosse, T.; Nijman, H.W.; Koelzer, V.H. & Church, D.N. (2020), Prognostic integrated image-based immune and molecular profiling in early-stage endometrial cancer, Cancer Immunology Research 8(12): 1508-1519.
- Sessa, C.; Colombo, N.; Creutzberg, C.L.; Concin, N.; Wimberger, P.; Curigliano, G.; Marinoni, K.; Douillard, J.Y.; Pentheroudakis, G.; Torri, V. & Rauh, S. (2020), Implementing clinical practice guidelines: time to assess it, ESMO Open 5(6).
- Zayed, S.; Nguyen, T.; Beriwal, S.; Creutzberg, C.L.; Kamrava, M.; Leung, E.W. & D'Souza, D.P. (2020), Red Blood Cell Transfusion Practices for Cervix Cancer Patients Undergoing Radiotherapy: An International Delphi Consensus Study, International Journal of Radiation Oncology - Biology - Physics 108(3): E465-E465.
- Brouwer, N.J.; Marinkovic, M.; Peters, F.P.; Hulshof, M.C.C.M.; Pieters, B.R.; Keizer, R.J.W. de; Horeweg, N.; Laman, M.S.; Bleeker, J.C.; Duinen, S.G. van; Jager, M.J.; Creutzberg, C.L. & Luyten, G.P.M. (2020), Management of conjunctival melanoma with local excision and adjuvant brachytherapy, Eye 35.
- Leon-Castillo, A.; Boer, S. de; Singh, N.; Mileshkin, L.; Fyles, A.; Leary, A.; Haie-Meder, C.; Smit, V.; Wilson, G.; Nout, R.; Horeweg, N.; Creutzberg, C. & Bosse, T. (2020), Importance of Histological Subtyping in TP53 Mutant Endometrial Carcinomas, Modern Pathology 33(SUPPL 2): 1095-1095.
- Leon-Castillo, A.; Boer, S. de; Singh, N.; Mileshkin, L.; Fyles, A.; Leary, A.; Haie-Meder, C.; Smit, V.; Wilson, G.; Nout, R.; Horeweg, N.; Creutzberg, C. & Bosse, T. (2020), Importance of Histological Subtyping in TP53 Mutant Endometrial Carcinomas, Laboratory Investigation 100(SUPPL 1): 1095-1095.
- Kortekaas, K.E.; Bastiaannet, E.; Doorn, H.C. van; Steenwijk, P.J.D. van; Ewing-Graham, P.C.; Creutzberg, C.L.; Akdeniz, K.; Nooij, L.S.; Burg, S.H. van der; Bosse, T. & Poelgeest, M.I.E. van (2020), Vulvar cancer subclassification by HPV and p53 status results in three clinically distinct subtypes, Gynecologic Oncology 159(3): 649-656.
- Boer, S.M. de; Powell, M.E.; Mileshkin, L.; Katsaros, D.; Bessette, P.; Haie-Meder, C.; Ottevanger, P.B.; Ledermann, J.A.; Khaw, P.; D'Amico, R.; Fyles, A.; Baron, M.H.; Jurgenliemk-Schulz, I.M.; Kitchener, H.C.; Nijman, H.W.; Wilson, G.; Brooks, S.; Gribaudo, S.; Provencher, D.; Hanzen, C.; Kruitwagen, R.F.; Smit, V.T.H.B.M.; Singh, N.; , V. do; Lissoni, A.; Nout, R.A.; Feeney, A.; Verhoeven-Adema, K.W.; Putter, H.; Creutzberg, C.L. & PORTEC Study Grp (2019), Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3), The Lancet Oncology 20(9).
- Boer, S.M. de; Nout, R.A.; Bosse, T. & Creutzberg, C.L. (2019), Adjuvant therapy for high-risk endometrial cancer: recent evidence and future directions, Expert Review of Anticancer Therapy 19(1): 51-60.
- Creutzberg, C.L.; Lu, K.H. & Fleming, G.F. (2019), Uterine Cancer: Adjuvant Therapy and Management of Metastatic Disease, Journal of Clinical Oncology 37(27): 2490-+.
- Kortekaas, K.E.; Bastiaannet, E.; Doom, H.C. van; Goddijn, I.F.; Rogaar, H.J.; Steenwijk, R.J.D.V. van; Ewing, P.C.; Creutzberg, C.L.; Akdeniz, K.; Nooij, L.S.; Burg, S.H. van der; Bosse, T. & Poelgeest, M.E. van (2019), DEVELOPMENT OF A RISK MODEL FOR SURVIVAL AND RECURRENCE IN PATIENTS WITH VULVAR SQUAMOUS CELL CARCINOMA, International Journal of Gynecological Cancer 29: A606-A606.
- Boer, S.M. de; Powell, M.E.; Mileshkin, L.; Katsaros, D.; Bessette, P.; Haie-Meder, C.; Ottevanger, P.B.; Ledermann, J.A.; Khaw, P.; D'Amico, R.; Fyles, A.; Baron, M.H.; Jurgenliemk-Schulz, I.M.; Kitchener, H.C.; Nijman, H.W.; Wilson, G.; Brooks, S.; Gribaudo, S.; Provencher, D.; Hanzen, C.; Kruitwagen, R.F.; Smit, V.T.H.B.M.; Singh, N.; , V. do; Lissoni, A.; Nout, R.A.; Feeney, A.; Verhoeven-Adema, K.W.; Putter, H.; Creutzberg, C.L. & PORTEC Study Grp (2019), Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial, The Lancet Oncology 20(9): 1273-1285.
- Wortman, B.G.; Nout, R.A.; Bosse, T. & Creutzberg, C.L. (2019), Selecting Adjuvant Treatment for Endometrial Carcinoma Using Molecular Risk Factors, Current Oncology Reports 21(9).
- Boer, S. de; Powell, M.E.; Mileshkin, L.; Katsaros, D.; Bessette, P.; Haie-Meder, C.; Ottevanger, P.B.; Ledermann, J.A.; Khaw, P.; Colombo, A.; Fyles, A.; Baron, M.H.; Jurgenliemk-Schulz, I.; Kitchener, H.; Nijman, H.W.; Kruitwagen, R.F.; Smit, V.T.; Nout, R.A.; Putter, H. & Creutzberg, C.L. (2019), Patterns of Recurrence and Survival in the Randomized Portec-3 Trial of Chemoradiotherapy for High-Risk Endometrial Cancer, International Journal of Radiation Oncology - Biology - Physics 105(1): S1-S2.
- Oonk, M.H.M.; Slomovitz, B.; Baldwin, P.; Doorn, H. van; Velden, J. van der; Hullu, J. de; Slangen, B.; Gaarenstroom, K.; Vergote, I.; Brannstrom, M.; Dorst, E. van; Driel, W. van; Hermans, R.; Nunns, D.; Widschwendter, M.; Nugent, D.; Holland, C.; DiSilvestro, P.; Sharma, A.; Mannel, R.; Boll, D.; Covens, A.; Cibula, D.; Provencher, D.; Luesley, D.; Ellis, P.; Duncan, T.; Tjiong, M.; Cruickshank, D.; Kjolhede, P.; Levenback, C.; Bouda, J.; Kieser, K.; Runnebaum, I.; Palle, C.; Spirtos, N.; O'Malley, D.; Leitao, M.; Geller, M.; Tamussino, K.; Dhar, K.; Tobias, D.; Borgfeldt, C.; Myers, T.; Lea, J.; Bailey, J.; Persson, P.; Monk, B.; Creutzberg, C.; Zee, A. van der & GROINSS-V II Study Grp (2019), RADIOTHERAPY INSTEAD OF INGUINOFEMORAL LYMPHADENECTOMY IN VULVAR CANCER PATIENTS WITH A METASTATIC SENTINEL NODE: RESULTS OF GROINSS-V II, International Journal of Gynecological Cancer 29: A14-A14.
- Leon-Castillo, A.; Boer, S.M. de; Powell, M.E.; Mileshkin, L.R.; Mackay, H.J.; Leary, A.; Nijman, H.W.; Singh, N.; Pollock, P.; Bessette, P.; Haie-Meder, C.; Smit, V.T.H.B.M.; Edmondson, R.J.; Putter, H.; Kitchener, H.C.; Crosbie, E.J.; Bruyn, M. de; Nout, R.A.; Horeweg, N.; Bosse, T. & Creutzberg, C.L. (2019), PROGNOSTIC RELEVANCE OF THE MOLECULAR CLASSIFICATION IN HIGH-RISK ENDOMETRIAL CANCER: ANALYSIS OF THE PORTEC-3 TRIAL, International Journal of Gynecological Cancer 29: A7-A8.
- Boer, F.L.; Eikelder, M.L.G. ten; Kapiteijn, E.H.; Creutzberg, C.L.; Galaal, K. & Poelgeest, M.I.E. van (2019), Vulvar malignant melanoma: Pathogenesis, clinical behaviour and management: Review of the literature, Cancer Treatment Reviews 73: 91-103.
- Creutzberg C. (2019), The role of postoperative radiotherapy in endometrial cancer: what have we learned of the PORTEC trials?, Radiotherapy and Oncology 133: S3-S3.
- Bagnoli, M.; Shi, T.Y.; Gourley, C.; Speiser, P.; Reuss, A.; Nijman, H.W.; Creutzberg, C.L.; Scholl, S.; Negrouk, A.; Brady, M.F.; Hasegawa, K.; Oda, K.; McNeish, I.A.; Kohn, E.C.; Oza, A.M.; MacKay, H.; Millan, D.; Bennett, K.; Scott, C. & Mezzanzanica, D. (2019), Gynecological cancers translational, research implementation, and harmonization, Cells 8(3).
- Horeweg, N.; Creutzberg, C.L.; Rijkmans, E.C.; Laman, M.S.; Velema, L.A.; Coen, V.L.M.A.; Stam, T.C.; Kerkhof, E.M.; Kroep, J.R.; Kroon, C.D. de & Nout, R.A. (2019), Efficacy and toxicity of chemoradiation with image-guided adaptive brachytherapy for locally advanced cervical cancer, International Journal of Gynecological Cancer 29(2): 257-265.
- Workel, H.H.; Lubbers, J.M.; Arnold, R.; Prins, T.M.; Vlies, P. van der; Lange, K. de; Bosse, T.; Gool, I.C. van; Eggink, F.A.; Wouters, M.C.A.; Komdeur, F.L.; Slikke, E.C. van der; Creutzberg, C.L.; Kol, A.; Plat, A.; Glaire, M.; Church, D.N.; Nijman, H.W. & Bruyn, M. de (2019), A Transcriptionally Distinct CXCL13(+)CD103(+)CD8(+) T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer, Cancer Immunology Research 7(5): 784-796.
- Wortman, B.; Astreinidou, E.; Laman, M.; Lutgens, L.; Steen-Banasik, E. van der; Slot, A.; Westerveld, H.; Winter, K. de; Berg, H. van den; Bloemers, M.; Stam, T.; Mens, J.; Zwanenburg, L.; Bijmolt, S.; Jurgenliemk-Schulz, I.; Snyers, A.; Creutzberg, C. & Nout, R. (2019), Brachytherapy quality assurance in the PORTEC-4a trial for high-intermediate risk endometrial cancer, Radiotherapy and Oncology 133: S198-S199.
- Creutzberg, C.L.; Leon-Castillo, A.; Boer, S.M. de; Powell, M.E.; Mileshkin, L.R.; Mackay, H.J.; Leary, A.; Nijman, H.W.; Singh, N.; Pollock, P.; Fyles, A.; Haie-Meder, C.; Smit, V.T.H.B.M.; Edmondson, R.J.; Putter, H.; Kitchener, H.C.; Crosbie, E.J.; Bruyn, M. de; Nout, R. & Bosse, T. (2019), Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: Impact on adjuvant therapy, Annals of Oncology 30: 899-+.
- Ezendam, N.P.M.; Rooij, B.H. de; Creutzberg, C.L.; Kruitwagen, R.F.P.M.; Lonkhuijzen, L.R. van; Apperloo, M.J.A.; Gerestein, K.; Baalbergen, A.; Boll, D.; Vos, M.C.; Poll-Franse, L.V. van de & ENSURE Study Grp (2019), EFFECT OF A REDUCED FOLLOW-UP SCHEDULE ON PATIENT SATISFACTION WITH CARE AMONG EARLY-STAGE ENDOMETRIAL CANCER PATIENTS: ONE-YEAR PRELIMINARY RESULTS OF THE ENSURE RANDOMIZED CONTROLLED TRIAL, International Journal of Gynecological Cancer 29: A173-A173.
- Amant, F.; Mirza, M.R.; Koskas, M. & Creutzberg, C.L. (2018), Cancer of the corpus uteri, International Journal of Gynecology & Obstetrics 143: 37-50.
- Greimel, E.; Lanceley, A.; Oberguggenberger, A.; Nordin, A.; Kuljanic, K.; Schmalz, C.; Arraras, J.I.; Chie, W.; Jensen, P.T.; Tomaszewski, K.A.; Creutzberg, C.L.; Galalae, R.; Toelen, H.; Inwald, E.C.; Bjelic-Radisic, V. & EORTC Quality Life Grp (2018), Differences in health care professionals' and cancer patients' views on sexual health issues, Psycho-Oncology 27(9): 2299-2302.
- Nout, R.A.; Powell, M.E.; Boer, S.M. de & Creutzberg, C.L. (2018), Treatment toxicity in endometrial cancer: can we identify and manage it better?, The Lancet Oncology 19(5): 602-602.
- Oberguggenberger, A.S.; Nagele, E.; Inwald, E.C.; Tomaszewski, K.; Lanceley, A.; Nordin, A.; Creutzberg, C.L.; Kuljanic, K.; Kardamakis, D.; Schmalz, C.; Arraras, J.; Costantini, A.; Almont, T.; Wei-Chu, C.; Dehandschutter, S.; Winters, Z.; Greimel, E. & EORTC Quality Life Grp (2018), Phase 1-3 of the cross-cultural development of an EORTC questionnaire for the assessment of sexual health in cancer patients: the EORTC SHQ-22, Cancer Medicine 7(3): 635-645.
- Creutzberg, C.L. & Bosse, T. (2018), Molecular risk stratification to direct therapy in endometrial cancer: ready for the clinic?, Annals of Oncology 29(5): 1081-1082.
- Ezendam, N.P.M.; Rooij, B.H. de; Kruitwagen, R.F.P.M.; Creutzberg, C.L.; Loon, I. van; Boll, D.; Vos, M.C. & Poll-Franse, L.V. van de (2018), ENdometrial cancer SURvivors' follow-up carE (ENSURE): Less is more? Evaluating patient satisfaction and cost-effectiveness of a reduced follow-up schedule: study protocol of a randomized controlled trial, Trials 19.
- Horeweg N., Creutzberg C. L., Rijkmans E. C., Laman M. S., Velema L. A., Coen V. L. M. A., Stam T. C., Kerkhof E. M., Kroep J. R., De Kroon C. D. & Nout R. A. (2018), Efficacy and toxicity of chemoradiation with brachytherapy for locally advanced cervical cancer, Radiotherapy and Oncology 127: S420-S421.
- Wortman, B.G.; Creutzberg, C.L.; Putter, H.; Jurgenliemk-Schulz, I.M.; Jobsen, J.J.; Lutgens, L.C.H.W.; Steen-Banasik, E.M. van der; Mens, J.W.M.; Slot, A.; Kroese, M.C.S.; Triest, B. van; Nijman, H.W.; Stelloo, E.; Bosse, T.; Boer, S.M. de; Putten, W.L.J. van; Smit, V.T.H.B.M.; Nout, R.A. & PORTEC Study Grp (2018), Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy, British Journal of Cancer 119(9): 1067-1074.
- Stephanie M. de Boer1* MD, Melanie E. Powell2 MD, Linda Mileshkin3 MD, Prof Dionyssios Katsaros4 MD, Prof Paul Bessette5 MD, Christine Haie-Meder6 MD, Petronella B. Ottevanger7 MD, Prof Jonathan A. Ledermann8 MD, Pearly Khaw9 MD, Alessandro Colombo10 MD, Prof Anthony Fyles11 MD, Marie-Helene Baron12 MD, Ina M. Jürgenliemk-Schulz13 MD, Prof Henry C. Kitchener14 MD, Prof Hans W. Nijman15 MD, Godfrey Wilson16 MD, Ilka Kolodziej17 MPH, Silvestro Carinelli18 MD, Ludy C.H.W. Lutgens19 MD, Prof Vincent T. Smit20 PhD, Naveena Singh21 MD, Remi A. Nout1 MD, Karen W. Verhoeven-Adema22 PhD, Prof Hein Putter23 PhD, Prof Carien L. Creutzberg1 MD & on behalf of the PORTEC study group#. (2018), Patterns of recurrence in the randomised PORTEC-3 trial of chemoradiotherapy for endometrial cancer.
- Marinkovic, M.; Horeweg, N.; Laman, M.S.; Bleeker, J.C.; Ketelaars, M.; Peters, F.P.; Luyten, G.P.M. & Creutzberg, C.L. (2018), Ruthenium-106 brachytherapy for iris and iridociliary melanomas, British Journal of Ophthalmology 102(8): 1154-1159.
- Auguste, A.; Genestie, C.; Bruyn, M. de; Adam, J.; Formal, A. le; Drusch, F.; Pautier, P.; Crosbie, E.J.; MacKay, H.; Kitchener, H.C.; Powell, M.; Pollock, P.M.; Mileshkin, L.; Edmondson, R.J.; Nout, R.; Nijman, H.W.; Creutzberg, C.L.; Bosse, T. & Leary, A. (2018), Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative, Modern Pathology 31(12): 1851-1861.
- Dostalek, L.; Avall-Lundqvist, E.; Creutzberg, C.L.; Kurdiani, D.; Ponce, J.; Dostalkova, I. & Cibula, D. (2018), ESGO Survey on Current Practice in the Management of Cervical Cancer, International Journal of Gynecological Cancer 28(6): 1226-1231.
- Brouwer Niels J., Marinkovic Marina, Peters Femke P., Hulshof Maarten C., Pieters Bradley R., de Keizer Rob J. W., Horeweg Nanda, Laman Mirjam S., Bleeker Jaco C., van Duinen Sjoerd G., Jager Martine J., Creutzberg Carien L. & Luyten Gregorius P. M. (2018), Adjuvant brachytherapy with strontium-90 or ruthenium-106 in conjunctival melanoma, Investigative Ophthalmology & Visual Science 59(9).
- Poll-Franse, L. van de; Oerlemans, S.; Bredart, A.; Kyriakou, C.; Sztankay, M.; Pallua, S.; Daniels, L.; Creutzberg, C.L.; Cocks, K.; Malak, S.; Caocci, G.; Molica, S.; Chie, W.C.; Efficace, F. & EORTC Quality Life Grp (2018), International development of four EORTC disease-specific quality of life questionnaires for patients with Hodgkin lymphoma, high- and low-grade non-Hodgkin lymphoma and chronic lymphocytic leukaemia, Quality of Life Research 27(2): 333-345.
- Wortman, B.G.; Bosse, T.; Nout, R.A.; Lutgens, L.C.H.W.; Steen-Banasik, E.M. van der; Westerveld, H.; Berg, H. van den; Slot, A.; Winter, K.A.J. de; Verhoeven-Adema, K.W.; Smit, V.T.H.B.M.; Creutzberg, C.L. & PORTEC Study Grp (2018), Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: Evaluation of the pilot phase of the PORTEC-4a trial, Gynecologic Oncology 151(1): 69-75.
- Boer, S.M. de; Wortman, B.G.; Bosse, T.; Powell, M.E.; Singh, N.; Hollema, H.; Wilson, G.; Chowdhury, M.N.; Mileshkin, L.; Pyman, J.; Katsaros, D.; Carinelli, S.; Fyles, A.; McLachlin, C.M.; Haie-Meder, C.; Duvillard, P.; Nout, R.A.; Verhoeven-Adema, K.W.; Putter, H.; Creutzberg, C.L.; Smit, V.T.H.B.M. & PORTEC Study Grp (2018), Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer., Annals of Oncology.
- Gool, I.C. van; Rayner, E.; Osse, E.M.; Nout, R.A.; Creutzberg, C.L.; Tomlinson, I.P.M.; Church, D.N.; Smit, V.T.H.B.M.; Wind, N. de; Bosse, T. & Drost, M. (2018), Adjuvant Treatment for POLE Proofreading Domain-Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues, Clinical Cancer Research 24(13): 3197-3203.
- Boer, S.M. de; Wortman, B.G.; Bosse, T.; Powell, M.E.; Singh, N.; Hollema, H.; Wilson, G.; Chowdhury, M.N.; Mileshkin, L.; Pyman, J.; Katsaros, D.; Carinelli, S.; Fyles, A.; McLachlin, C.M.; Haie-Meder, C.; Duvillard, P.; Nout, R.A.; Verhoeven-Adema, K.W.; Putter, H.; Creutzberg, C.L.; Smit, V.T.H.B.M. & PORTEC Study Grp (2018), Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer, Annals of Oncology 29(2): 424-430.
- Boer, S.M. de; Powell, M.E.; Mileshkin, L.; Katsaros, D.; Bessette, P.; Haie-Meder, C.; Ottevanger, P.B.; Ledermann, J.A.; Khaw, P.; Colombo, A.; Fyles, A.; Baron, M.H.; Jurgenliemk-Schulz, I.M.; Kitchener, H.C.; Nijman, H.W.; Wilson, G.; Brooks, S.; Carinelli, S.; Provencher, D.; Hanzen, C.; Lutgens, L.C.H.W.; Smit, V.T.H.B.M.; Singh, N.; , V. do; D'Amico, R.; Nout, R.A.; Feeney, A.; Verhoeven-Adema, K.W.; Putter, H.; Creutzberg, C.L. & PORTEC Study Grp (2018), Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial, Lancet Oncology 19(3): 295-309.
- Khaw, P.; , V. do; Lim, K.; Cunninghame, J.; Dixon, J.; Moore, A.; Fyles, A.; Johnson, C.; Powell, M.; Haie-Meder, C.; Vassie, J.; Kahl, K.; Bailey, M.; Kaminski, S.; Gordon, C.; Cook, O.; Harris, M.; Mileshkin, L. & Creutzberg, C. (2018), Results of International Quality Assurance Radiation Therapy (QART) procedures for the PORTEC-3 trial, International Journal of Gynecological Cancer 28: 43-43.
- Boer, S.M. de; Nout, R.A.; Bosse, T. & Creutzberg, C.L. (2018), Adjuvant therapy for high-risk endometrial cancer: recent evidence and future directions., Expert Review of Anticancer Therapy.
- Gool, I.C. van; Ubachs, J.E.H.; Stelloo, E.; Kroon, C.D. de; Goeman, J.J.; Smit, V.T.H.B.M.; Creutzberg, C.L. & Bosse, T. (2018), Blinded histopathological characterisation of POLE exonuclease domain-mutant endometrial cancers: sheep in wolf's clothing, Histopathology 72(2): 248-258.
- Peters, F.P.; Marinkovic, M.; Horeweg, N.; Laman, M.S.; Bleeker, J.C.; Ketelaars, M.; Luyten, G.P.M. & Creutzberg, C.L. (2017), Ruthenium-106 brachytherapy for iris and choroidal body melanomas, Radiotherapy and Oncology 123: S195-S195.
- Boer, S.M. de; Powell, M.E.; Mileshkin, L.R.; Katsaros, D.; Bessette, P.; Haie-Meder, C.; Ottevanger, P.B.; Ledermann, J.A.; Khaw, P.; Colombo, A.; Fyles, A.W.; Baron, M.H.; Kitchener, H.C.; Nijman, H.; Kruitwagen, R.F.P.M.; Jurgenliemk-Schulz, I.M.; Nout, R.A.; Smit, V.T.H.B.M.; Putter, H. & Creutzberg, C.L. (2017), Final results of the international randomized PORTEC-3 trial of adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-risk endometrial cancer, Journal of Clinical Oncology 35.
- Nout, R.; Astreinidou, E.; Laman, M. & Creutzberg, C. (2017), Postoperative vaginal brachytherapy: a quality assurance dummy-run procedure in the PORTEC-4 trial, Radiotherapy and Oncology 123: S198-S198.
- Gool, I.C. van; Rayner, E.; Osse, E.M.; Tomlinson, I.P.M.; Smit, V.T.H.B.M.; Creutzberg, C.L.; Church, D.N.; Wind, N. de; Bosse, T. & Drost, M. (2017), PROGNOSTIC BENEFIT OF POLE EXONUCLEASE DOMAIN MUTATIONS IN ENDOMETRIAL CANCER CANNOT BE EXPLAINED BY INCREASED SENSITIVITY TO ADJUVANT TREATMENT STRATEGIES, International Journal of Gynecological Cancer 27: 1239-1239.
- Boer, S.M. de; Powell, M.E.; Mileshkin, L.R.; Katsaros, D.; Bessette, P.; Haie-Meder, C.; Ottevanger, P.B.; Ledermann, J.A.; Khaw, P.; Colombo, A.; Fyles, A.W.; Baron, M.H.; Kitchener, H.C.; Nijman, H.; Kruitwagen, R.F.P.M.; Jurgenliemk-Schulz, I.M.; Nout, R.A.; Smit, V.T.H.B.M.; Putter, H. & Creutzberg, C.L. (2017), Final results of the international randomized PORTEC-3 trial of adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-risk endometrial cancer.
- Auguste, A.; Genestie, C.; DeBruyn, M.; Adam, J.; Drusch, F.; LeFormal-Ensarguex, A.; Pautier, P.; Crosbie, E.; MacKay, H.; Kitchener, H.; Powell, M.; Pollock, P.; Mileshkin, L.; Edmonson, R.; Nout, R.; Nijman, H.; Creutzberg, C.; Bosse, T. & Leary, A. (2017), REFINEMENT OF HIGH-RISK ENDOMETRIAL-CANCER (HR-EC) CLASSIFICATION USING DNA DAMAGE RESPONSE (DDR) BIOMARKERS: A TRANSPORTEC INITIATIVE, International Journal of Gynecological Cancer 27: 31-31.
- Auguste, A.; Genestie, C.; DeBruyn, M.; Adam, J.; Drusch, F.; LeFormal-Ensarguex, A.; Pautier, P.; Crosbie, E.; MacKay, H.; Kitchener, H.; Powell, M.; Pollock, P.; Mileshkin, L.; Edmonson, R.; Nout, R.; Nijman, H.; Creutzberg, C.; Bosse, T. & Leary, A. (2017), REFINEMENT OF HIGH-RISK ENDOMETRIAL-CANCER (HR-EC) CLASSIFICATION USING DNA DAMAGE RESPONSE (DDR) BIOMARKERS: A TRANSPORTEC INITIATIVE, International Journal of Gynecological Cancer 27: 1029-1029.
- Querleu, D.; Planchamp, F.; Chiva, L.; Fotopoulou, C.; Barton, D.; Cibula, D.; Aletti, G.; Carinelli, S.; Creutzberg, C.; Davidson, B.; Harter, P.; Lundvall, L.; Marth, C.; Morice, P.; Rafii, A.; Ray-Coquard, I.; Rockall, A.; Sessa, C.; Zee, A. van der; Vergote, I. & duBois, A. (2017), European Society of Gynaecological Oncology (ESGO) Guidelines for Ovarian Cancer Surgery, International Journal of Gynecological Cancer 27(7): 1534-1542.
- Wiltink, L.M.; Nout, R.A.; Fiocco, M.; Creutzberg, C.L. & Marijnen, C.A.M. (2017), Postoperative Pelvic Radiotherapy in Patients With Endometrial Cancer May Increase the Risk for Secondary Pelvic Cancers: A Post Hoc Analysis of Results From the TME, PORTEC-1, and PORTEC-2 Trials Reply, Journal of Clinical Oncology 35(16): 1862-+.
- Eggink, F.A.; Mom, C.H.; Bouwman, K.; Boll, D.; Becker, J.H.; Creutzberg, C.L.; Niemeijer, G.C.; Driel, W.J. van; Reyners, A.K.; Zee, A.G. van der; Bremer, G.L.; Ezendam, N.P.; Kruitwagen, R.F.; Pijnenborg, J.M.; Hollema, H.; Nijman, H.W. & Aa, M.A. van der (2017), Less-favourable prognosis for low-risk endometrial cancer patients with a discordant pre- versus post-operative risk stratification (vol 78, pg 82, 2017), European Journal of Cancer 84: 370-370.
- Colombo, N.; Creutzberg, C.; Querleu, D.; Barahona, M.; Sessa, C. & ESMO Guidelines Comm (2017), Appendix 5: Endometrial cancer: eUpdate published online 8 June 2017 (www.esmo.org/Guidelines/Gynaecological-Cancers), Annals of Oncology 28: 153-156.
- Depreeuw, J.; Stelloo, E.; Osse, E.M.; Creutzberg, C.L.; Nout, R.A.; Moisse, M.; Garcia-Dios, D.A.; Dewaele, M.; Willekens, K.; Marine, J.C.; Matias-Guiu, X.; Amant, F.; Lambrechts, D. & Bosse, T. (2017), Amplification of 1q32.1 Refines the Molecular Classification of Endometrial Carcinoma, Clinical Cancer Research 23(23): 7232-7241.
- Bakker, R.M.; Pieterse, Q.D.; Lonkhuijzen, L.R.C.W. van; Trimbos, B.J.B.M.Z.; Creutzberg, C.L.; Kenter, G.G.; Kroon, C.D. de & Kuile, M.M. ter (2017), A Controlled Study on Vaginal Blood Flow During Sexual Arousal Among Early-Stage Cervical Cancer Survivors Treated With Conventional Radical or Nerve-Sparing Surgery With or Without Radiotherapy, International Journal of Gynecological Cancer 27(5): 1051-1057.
- Eggink, F.A.; Mom, C.H.; Bouwman, K.; Boll, D.; Becker, J.H.; Creutzberg, C.L.; Niemeijer, G.C.; Driel, W.J. van; Reyners, A.K.; Zee, A.G. van der; Bremer, G.L.; Ezendam, N.P.; Kruitwagen, R.F.; Pijnenborg, J.M.; Hollema, H.; Nijman, H.W. & Aa, M.A. van der (2017), Less-favourable prognosis for low-risk endometrial cancer patients with a discordant pre-versus post-operative risk stratification, European Journal of Cancer 78: 82-90.
- Eggink, F.A.; Gool, I.C. van; Leary, A.; Pollock, P.M.; Crosbie, E.J.; Mileshkin, L.; Jordanova, E.S.; Adam, J.; Freeman-Mills, L.; Church, D.N.; Creutzberg, C.L.; Bruyn, M. de; Nijman, H.W. & Bosse, T. (2017), Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition, OncoImmunology 6(2).
- Bakker, R.M.; Kenter, G.G.; Creutzberg, C.L.; Stiggelbout, A.M.; Derks, M.; Mingelen, W.; Kroon, C.D.; Vermeer, W.M. & Kuile, M.M. ter (2017), Sexual distress and associated factors among cervical cancer survivors: A cross-sectional multicenter observational study, Psycho-Oncology 26(10): 1470-1477.
- Luyten, G.; Marinkovic, M.; Sommers, L.; Horeweg, N.; Fiocco, M.; Bleeker, J. & Creutzberg, C.L. (2017), Ruthenium-106 brachytherapy for uveal melanoma without transpupillary thermotherapy: similar efficacy with improved visual outcome, Acta Ophthalmologica 95: 15-15.
- Stelloo, E.; Jansen, A.M.L.; Osse, E.M.; Nout, R.A.; Creutzberg, C.L.; Ruano, D.; Church, D.N.; Morreau, H.; Smit, V.T.H.B.M.; Wezel, T. van & Bosse, T. (2017), Practical guidance for mismatch repair-deficiency testing in endometrial cancer, Annals of Oncology 28(1): 96-102.
- Edmondson, R.J.; Crosbie, E.J.; Nickkho-Amiry, M.; Kaufmann, A.; Stelloo, E.; Nijman, H.W.; Leary, A.; Auguste, A.; Mileshkin, L.; Pollock, P.; MacKay, H.J.; Powell, M.E.; Bosse, T.; Creutzberg, C.L. & Kitchener, H.C. (2017), Markers of the p53 pathway further refine molecular profiling in high-risk endometrial cancer: A TransPORTEC initiative, Gynecologic Oncology 146(2): 327-333.
- Bakker, R.M.; Mens, J.W.M.; Groot, H.E. de; Tuijnman-Raasveld, C.C.; Braat, C.; Hompus, W.C.P.; Poelman, J.G.M.; Laman, M.S.; Velema, L.A.; Kroon, C.D. de; Doorn, H.C. van; Creutzberg, C.L. & Kuile, M.M. ter (2017), A nurse-led sexual rehabilitation intervention after radiotherapy for gynecological cancer, Supportive Care in Cancer 25(3): 729-737.
- Esterik, M. van; Gool, I.C. van; Kroon, C.D. de; Nout, R.A.; Creutzberg, C.L.; Smit, V.T.H.B.M.; Bosse, T. & Stelloo, E. (2017), Limited impact of intratumour heterogeneity on molecular risk assignment in endometrial cancer, Oncotarget 8(15): 25542-25551.
- Marinkovic M., Horeweg N., Fiocco M., Peters F.P., Sommers L.W., Laman M.S., Bleeker J.C., Ketelaars M., Luyten G.P.M. & Creutzberg C.L. (2016), Ruthenium-106 brachytherapy for choroidal melanoma without transpupillary thermotherapy: Similar efficacy with improved visual outcome, European Journal of Cancer 68: 106-113.
- Peters, F.P.; Marinkovic, M.; Horeweg, N.; Sommers, L.; Fiocco, M.; Bleeker, J.C.; Ketelaars, M.; Luyten, G.P.M. & Creutzberg, C.L. (2016), Ruthenium-106 brachytherapy for choroidal melanoma: high efficacy with improved visual outcome., Radiotherapy and Oncology 119: S357-S358.
- Chuang, L.T.; Randall, T.C.; Denny, L.; Johnston, C.M.; Schmeler, K.M.; Covens, A.L.; Cibula, D.; Bookman, M.A.; Rawal, S.; DePetrillo, D.; Nam, J.H.; Goodman, A.; Naik, R.; Manchanda, R.; Gaffney, D.K.; Small, W.; Creutzberg, C.; Rattray, C.; Kesic, V.; Paraja, R.; Eiken, M.; Belleson, K.; Coleman, R.L.; Barakat, R.R.; Trimble, E.L. & Quinn, M. (2016), Sister Society Meeting on Global Education Development and Collaboration: Meeting Report., International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.
- Sande, M. van de; Creutzberg, C.L.; Water, S. van de; Sharfo, A.W. & Hoogeman, M.S. (2016), Advantage of IMPT over IMRT in treatment of gynaecological cancer with para-aortic nodal involvement, Radiotherapy and Oncology 119: S263-S264.
- Stelloo, E.; Jansen, A.; Osse, E.; Nout, R.; Ruano, D.; Wezel, T. van; Creutzberg, C.; Smit, V.; Morreau, H. & Bosse, E. (2016), Comprehensive analysis of microsatellite instability and mismatch repair protein expression in nearly 700 endometrial cancers, Virchows Archiv 469: S19-S19.
- Boer, S.M. de; Powell, M.E.; Mileshkin, L.; Katsaros, D.; Bessette, P.; Haie-Meder, C.; Ottevanger, P.B.; Ledermann, J.A.; Khaw, P.; Colombo, A.; Fyles, A.; Baron, M.H.; Kitchener, H.C.; Nijman, H.W.; Kruitwagen, R.F.; Nout, R.A.; Verhoeven-Adema, K.W.; Smit, V.T.; Putter, H.; Creutzberg, C.L. & PORTEC Study Grp (2016), Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial., The Lancet. Oncology.
- Marinkovic, M.; Horeweg, N.; Fiocco, M.; Peters, F.P.; Sommers, L.W.; Laman, M.S.; Bleeker, J.C.; Ketelaars, M.; Luyten, G.P.M. & Creutzberg, C.L. (2016), Ruthenium-106 brachytherapy for choroidal melanoma without transpupillary thermotherapy: Similar efficacy with improved visual outcome, European Journal of Cancer 68: 106-113.
- Eggink F. A., Mom C. H., Bouwman K., Boll D., Becker J., Creutzberg C. L., Niemeijer G. C., van Driel W. J., Reyners A., van der Zee A. G., Bremer G. L., Ezendam N. P., Kruitwagen R. F., Pijnenborg J. M., Hollema H., Nijman H. W. & van der Aa M. A. (2016), UNFAVORABLE PROGNOSIS FOR LOW RISK ENDOMETRIAL CANCER PATIENTS WITH A DISCORDANT PRE-VERSUS POSTOPERATIVE RISK STRATIFICATION, International Journal of Gynecological Cancer 26: 50-51.
- Bakker, R.; Mens, J.W.; Groot, E. de; Tuijnman-Raasveld, C.; Braat, C.; Hompus, W.; Poelman, J.; Laman, M.; Kroon, C. de; Doorn, L. van; Creutzberg, C. & Kuile, M. ter (2016), A sexual rehabilitation programme for gynaecological cancer patients after radiation therapy: Final results of a pilot-study, Psycho-Oncology 25(SP. S3): 185-185.
- Bakker, R.; Mens, J.W.; Groot, E. de; Tuijnman-Raasveld, C.; Braat, C.; Hompus, W.; Poelman, J.; Laman, M.; Velema, L.; Kroon, C. de; Doorn, L. van; Kuile, M. ter & Creutzberg, C. (2016), A SEXUAL REHABILITATION PROGRAMME FOR GYNECOLOGICAL CANCER PATIENTS AFTER RADIATION THERAPY: FINAL RESULTS OF A PILOT STUDY, International Journal of Gynecological Cancer 26: 588-588.
- Morice, P.; Leary, A.; Creutzberg, C.; Abu-Rustum, N. & Darai, E. (2016), Endometrial cancer, Lancet 387(10023): 1094-1108.
- van Goole I., Ubachs J., Steno E., Ter Haar N., Smit V., Creutzberg C. & Bosse T. (2016), Blinded in-depth characterisation reveals distinct features associated with POLE proofreading domain mutations in endometrial cancer, facilitating clinical implementation, Virchows Archiv 469: S20-S20.
- Querleu, D.; Planchamp, F.; Chiva, L.; Fotopoulou, C.; Barton, D.; Cibula, D.; Aletti, G.; Carinelli, S.; Creutzberg, C.; Davidson, B.; Harter, P.; Lundvall, L.; Marth, C.; Morice, P.; Rafii, A.; Ray-Coquard, I.; Rockall, A.; Sessa, C.; Zee, A. van der; Vergote, I. & Bois, A. du (2016), European Society of Gynaecologic Oncology Quality Indicators for Advanced Ovarian Cancer Surgery, International Journal of Gynecological Cancer 26(7): 1354-1363.
- Stelloo, E.; Nout, R.A.; Osse, E.M.; Jurgenliemk-Schulz, I.J.; Jobsen, J.J.; Lutgens, L.C.; Steen-Banasik, E.M. van der; Nijman, H.W.; Putter, H.; Bosse, T.; Creutzberg, C.L. & Smit, V.T.H.B.M. (2016), Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts, Clinical Cancer Research 22(16): 4215-4224.
- van Esterik M., van Gool I., Nout R., Creutzberg C., Smit V., Bosse T. & Stelloo E. (2016), Insight in intratumour genetic heterogeneity in endometrial cancer, Virchows Archiv 469: S19-S19.
- Lutgens, L.C.H.W.; Koper, P.C.M.; Jobsen, J.J.; Steen-Banasik, E.M. van der; Creutzberg, C.L.; Berg, H.A. van den; Ottevanger, P.B.; Rhoon, G.C. van; Doorm, H.C. van; Houben, R. & Zee, J. van der (2016), Radiation therapy combined with hyperthermia versus cisplatin for locally advanced cervical cancer: Results of the randomized RADCHOC trial, Radiotherapy and Oncology 120(3): 378-382.
- Jameson, M.G.; McNamara, J.; Bailey, M.; Metcalfe, P.E.; Holloway, L.C.; Foo, K.; , V. do; Mileshkin, L.; Creutzberg, C.L. & Khaw, P. (2016), Results of the Australasian (Trans-Tasman Oncology Group) radiotherapy benchmarking exercise in preparation for participation in the PORTEC-3 trial, Journal of Medical Imaging and Radiation Oncology 60(4): 554-559.
- Boer, S.M. de; Powell, M.E.; Mileshkin, L.; Katsaros, D.; Bessette, P.; Haie-Meder, C.; Ottevanger, P.B.; Ledermann, J.A.; Khaw, P.; Colombo, A.; Fyles, A.; Baron, M.H.; Kitchener, H.C.; Nijman, H.W.; Kruitwagen, R.F.; Nout, R.A.; Verhoeven-Adema, K.W.; Smit, V.T.; Putter, H.; Creutzberg, C.L. & PORTEC Study Grp (2016), Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial, Lancet Oncology 17(8): 1114-1126.
- Nooij, L.S.; Slot, M.A. van der; Dekkers, O.M.; Stijnen, T.; Gaarenstroom, K.N.; Creutzberg, C.L.; Smit, V.T.H.B.M.; Bosse, T. & Poelgeest, M.I.E. van (2016), Tumour-free margins in vulvar squamous cell carcinoma: Does distance really matter?, European Journal of Cancer 65: 139-149.
- Sande, M.A.E. van de; Creutzberg, C.L.; Water, S. van de; Sharfo, A.W. & Hoogeman, M.S. (2016), Which cervical and endometrial cancer patients will benefit most from intensity-modulated proton therapy?, Radiotherapy and Oncology 120(3): 397-403.
- Bakker, R.M.; Mens, J.W.M.; Groot, H.E. de; Tuijnman-Raasveld, C.C.; Braat, C.; Hompus, W.C.P.; Poelman, J.G.M.; Laman, M.S.; Velema, L.A.; Kroon, C.D. de; Doorn, H.C. van; Creutzberg, C.L. & Kuile, M.M. ter (2016), A nurse-led sexual rehabilitation intervention after radiotherapy for gynecological cancer, Supportive Care in Cancer.
- Colombo, N.; Creutzberg, C.; Amant, F.; Bosse, T.; Gonzalez-Martin, A.; Ledermann, J.; Marth, C.; Nout, R.; Querleu, D.; Mirza, M.R.; Sessa, C. & ESMO-ESGO-ESTRO Endometrial Conse (2016), ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer Diagnosis, Treatment and Follow-up, International Journal of Gynecological Cancer 26(1): 2-30.
- Creutzberg, C.L. (2016), Hyperbaric oxygen therapy for radiation-induced injury: evidence is needed, Lancet Oncology 17(2): 132-134.
- Stelloo, E.; Versluis, M.A.; Nijman, H.W.; Bruyn, M. de; Plat, A.; Osse, E.M.; Dijk, R.H. van; Nout, R.A.; Creutzberg, C.L.; Bock, G.H. de; Smit, V.T.; Bosse, T. & Hollema, H. (2016), Microsatellite instability derived JAK1 frameshift mutations are associated with tumor immune evasion in endometrioid endometrial cancer, Oncotarget 7(26): 39885-39893.
- Gool, I.C. van; Stelloo, E.; Nout, R.A.; Nijman, H.W.; Edmondson, R.J.; Church, D.N.; MacKay, H.J.; Leary, A.; Powell, M.E.; Mileshkin, L.; Creutzberg, C.L.; Smit, V.T.H.B.M. & Bosse, T. (2016), Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer, Modern Pathology 29(2): 174-181.
- Chuang, L.T.; Randall, T.C.; Denny, L.; Johnston, C.M.; Schmeler, K.M.; Covens, A.L.; Cibula, D.; Bookman, M.A.; Rawal, S.; DePetrillo, D.; Nam, J.H.; Goodman, A.; Naik, R.; Manchanda, R.; Gaffney, D.K.; Small, W.; Creutzberg, C.; Rattray, C.; Kesic, V.; Paraja, R.; Eiken, M.; Belleson, K.; Coleman, R.L.; Barakat, R.R.; Trimble, E.L. & Quinn, M. (2016), Sister Society Meeting on Global Education Development and Collaboration Meeting Report, International Journal of Gynecological Cancer 26(6): 1186-1188.
- Colombo, N.; Creutzberg, C.; Amant, F.; Bosse, T.; Gonzalez-Martin, A.; Ledermann, J.; Marth, C.; Nout, R.; Querleu, D.; Mirza, M.R.; Sessa, C. & ESMO-ESGO-ESTRO Endometrial Consen (2016), ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up, Annals of Oncology 27(1): 16-41.
- Eggink F., van Gool I. C., Leary A., Pollock P. M., Crosbie E. J., Mileshkin L., Adam J., Church D., Creutzberg C. L., de Bruyn M., Nijman H. W. & Bosse T. (2016), A COMBINED MOLECULAR AND IMMUNOLOGICAL STRATIFICATION STRATEGY FOR IMMUNOTHERAPEUTIC TREATMENT OF HIGH RISK ENDOMETRIAL CANCER, International Journal of Gynecological Cancer 26: 47-48.
- Boer, S.M. de; Wortman, B.; Bosse, T.; Powell, M.E.; Singh, N.; Hollema, H.; Wilson, G.; Mileshkin, L.; Pyman, J.; Katsaros, D.; Carinelli, S.; Fyles, A.; McLachlin, C.M.; Haie-Meder, C.; Duvillard, P.; Nout, R.A.; Verhoeven-Adema, K.W.; Putter, H.; Creutzberg, C.L. & Smit, V.T. (2016), Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high risk endometrial cancer, International Journal of Gynecological Cancer 26: 220-221.
- Depreeuw J., Stelloo E., Osse E. M., Creutzberg C. L., Nout R. A., Marine J. C., Moisse M., Annibali D., Matias-Guiu X., Amant F., Lambrechts D. & Bosse T. (2016), Genomic landscape of copy number alterations identifies MDM4 as a prognostic significant and novel therapeutic target in endometrial cancer, International Journal of Gynecological Cancer 26: 58-58.
- Blinman, P.; Mileshkin, L.; Khaw, P.; Goss, G.; Johnson, C.; Capp, A.; Brooks, S.; Wain, G.; Kolodziej, I.; Veillard, A.S.; O'Connell, R.; Creutzberg, C.L.; Stockler, M.R.; ANZGOG & PORTEC Grp (2016), Patients' and clinicians' preferences for adjuvant chemotherapy in endometrial cancer: an ANZGOG substudy of the PORTEC-3 intergroup randomised trial, British Journal of Cancer 115(10): 1179-1185.
- Nooij, L.S.; Brand, F.A.M.; Gaarenstroom, K.N.; Creutzberg, C.L.; Hullu, J.A. de & Poelgeest, M.I.E. van (2016), Risk factors and treatment for recurrent vulvar squamous cell carcinoma, Critical Reviews in Oncology/Hematology 106: 1-13.
- Bakker, R.M.; Kenter, G.G.; Creutzberg, C.L.; Stiggelbout, A.M.; Derks, M.; Mingelen, W.; Kroon, C.D.; Vermeer, W.M. & Kuile, M.M. ter (2016), Sexual distress and associated factors among cervical cancer survivors, Psycho-Oncology.
- Boer, S.M. de; Nout, R.A.; Putter, H.; Jurgenliemk-Schulz, I.M.; Jobsen, J.J.; Lutgens, L.C.H.W.; Steen-Banasik, E.M. van der; Mens, J.W.M.; Slot, A.; Kroese, M.C.S.; Nijman, H.W. & Creutzberg, C.L. (2015), Long-term bowel and bladder symptoms after pelvic radiotherapy or vaginal brachytherapy in the PORTEC-2 trial, Radiotherapy & Oncology 115: S213-S213.
- Bakker, R.; Mens, J.W.M.; Creutzberg, C.L.; Groot, H.E. de; Tuijnman-Raasveld, C.C.; Braat, C.; Hompus, W.C.P.; Poelman, J.G.M.; Laman, S.; Kroon, C.D. de; Doorn, H.C. van & Kuile, M.M. ter (2015), A PILOT-STUDY OF A SEXUAL REHABILITATION PROGRAMME FOR GYNECOLOGICAL CANCER PATIENTS AFTER PELVIC RADIATION THERAPY., International Journal of Gynecological Cancer 25(9): 608-608.
- Stelloo, E.; Nout, R.A.; Osse, E.M.; Jurgenliemk-Schulz, I.M.; Jobsen, J.J.; Lutgens, L.C.; Steen-Banasik, E.M. van der; Nijman, H.W.; Putter, H.; Bosse, T.; Creutzberg, C.L. & Smit, V.T. (2015), IMPROVED RISK ASSESSMENT BY MOLECULAR GENETIC PROFILING IN EARLY STAGE ENDOMETRIAL CANCER: A POOLED PORTEC-1 AND-2 ANALYSIS, International Journal of Gynecological Cancer 25(9): 11-12.
- Linthorst, M.; Baaijens, M.; Wiggenraad, R.; Creutzberg, C.; Ghidey, W.; Rhoon, G.C. van & Zee, J. van der (2015), Local control rate after the combination of re-irradiation and hyperthermia for irresectable recurrent breast cancer: Results in 248 patients, Radiotherapy and Oncology 117(2): 217-222.
- Nooij, L.S.; Ongkiehong, P.J.; Zwet, E.W. van; Bosse, T.; Creutzberg, C.L.; Gaarenstroom, K.N. & Poelgeest, M.I.E. van (2015), NODAL DEBULKING VERSUS FULL INGUINOFEMORAL LYMPHADENECTOMY AND RISK OF RECURRENCE IN LYMPH NODE POSITIVE VULVAR SQUAMOUS CELL CARCINOMA PATIENTS, International Journal of Gynecological Cancer 25(9): 680-680.
- Gool, I.C. van; Stelloo, E.; Nout, R.A.; Nijman, H.W.; Edmondson, R.J.; Church, D.N.; MacKay, H.J.; Leary, A.; Powell, M.E.; Mileshkin, L.; Creutzberg, C.L.; Smit, V. & Bosse, T. (2015), PROGNOSTIC VALUE OF L1CAM EXPRESSION AND ITS ASSOCIATION WITH MUTANT P53 EXPRESSION IN HIGH-RISK ENDOMETRIAL CANCER PATIENTS: A TRANSPORTEC STUDY, International Journal of Gynecological Cancer 25(9): 258-259.
- Bosse, T.; Peters, E.E.M.; Creutzberg, C.L.; Jurenliemk-Schulz, I.M.; Jobsen, J.J.; Mens, J.W.M.; Lutgens, L.C.H.W.; Steen-Banasik, E.M. van der; Smit, V.T.H.B.M. & Nout, R.A. (2015), Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer, European Journal of Cancer 51(13).
- Wiltink, L.M.; Nout, R.A.; Fiocco, M.; Kranenbarg, E.M.K.; Jurgenliemk-Schulz, I.M.; Jobsen, J.J.; Nagtegaal, I.D.; Rutten, H.J.T.; Velde, C.J.H. van de; Creutzberg, C.L. & Marijnen, C.A.M. (2015), No Increased Risk of Second Cancer After Radiotherapy in Patients Treated for Rectal or Endometrial Cancer in the Randomized TME, PORTEC-1, and PORTEC-2 Trials., Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
- Bosse, T.; Peters, E.E.M.; Creutzberg, C.L.; Jurenliemk-Schulz, I.M.; Jobsen, J.J.; Mens, J.W.M.; Lutgens, L.C.H.W.; Steen-Banasik, E.M. van der; Smit, V.T.H.B.M. & Nout, R.A. (2015), Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer--A pooled analysis of PORTEC 1 and 2 trials., European journal of cancer (Oxford, England : 1990).
- Creutzberg, C.L.; Boer, S.M. de; Putter, H.; Powell, M.; Mileshkin, L.R.; Katsaros, D.; Bessette, P.; Haie-Meder, C.; Ledermann, J.A.; Ottevanger, P.B.; Khaw, P.; Colombo, A.; Fyles, A.W.; Baron, M.H.; Nijman, H.W.; Nout, R.A.; Smit, V.T.H.B.M.; Verhoeven-Adema, K.; Kruitwagen, R.F.P.M. & Kitchener, H.C. (2015), Adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-risk endometrial cancer: Toxicity and quality-of-life results of the randomized PORTEC-3 trial.
- Boer, S.M. de; Powell, M.E.; Mileshkin, L.; Katsaros, D.; Bessette, P.; Haie-Meder, C.; Nout, R.A.; Kitchener, H.C.; Ottevanger, P.B.; Khaw, P.; Colombo, A.; Fyles, A.; Baron, M.H.; Nijman, H.W.; Kruitwagen, R.; Ledermann, J.; Verhoeven-Adema, K.W.; Smit, V.T.; Putter, H. & Creutzberg, C.L. (2015), RELATION BETWEEN PATIENT AND PHYSICIAN REPORTED TOXICITY IN THE RANDOMISED PORTEC-3 TRIAL OF RADIATION THERAPY (RT) WITH OR WITHOUT CHEMOTHERAPY FOR ENDOMETRIAL CANCER, International Journal of Gynecological Cancer 25(9): 278-279.
- Kondalsamy-Chennakesavan, S.; Nasir, B.; Creutzberg, C.L.; Stiphout, R.G.P.M. van; Nout, R.A.; Lutgens, L.C.H.W.; Jurgenliemk-Schulz, M.; Lambin, P.; Kwan, M.M.S. & Obermair, A. (2015), VALIDATION OF THE AUSTRALIAN UTERINE CANCER NOMOGRAMS TO PREDICT LOCAL OR DISTANT RECURRENCE USING PORTEC TRIALS DATASET, International Journal of Gynecological Cancer 25(9): 289-290.
- Lim, K.; Erickson, B.; Juurgenliemk-Schulz, I.M.; Gaffney, D.; Creutzberg, C.L.; Viswanathan, A.; Portelance, L.; Beriwal, S.; Wolfson, A.; Bosch, W.; Santos, J.D.L.; Yashar, C.; Jhingran, A.; Varia, M.; Naqa, I. el; King, B. & Fyles, A. (2015), Variability in clinical target volume delineation for intensity modulated radiation therapy in 3 challenging cervix cancer scenarios, Practical Radiation Oncology 5(6): E557-E565.
- Creutzberg, C.L.; Boer, S.M. de; Putter, H.; Powell, M.; Mileshkin, L.R.; Katsaros, D.; Bessette, P.; Haie-Meder, C.; Ledermann, J.A.; Ottevanger, P.B.; Khaw, P.; Colombo, A.; Fyles, A.W.; Baron, M.H.; Nijman, H.W.; Nout, R.A.; Smit, V.T.H.B.M.; Verhoeven-Adema, K.; Kruitwagen, R.F.P.M. & Kitchener, H.C. (2015), Adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-risk endometrial cancer: Toxicity and quality-of-life results of the randomized PORTEC-3 trial., Journal of Clinical Oncology 33(15).
- Dogrusoz, M.; Kroes, W.G.M.; Duinen, S.G. van; Creutzberg, C.L.; Versluis, M.; Bleeker, J.C.; Marinkovic, M.; Luyten, G.P.M. & Jager, M.J. (2015), Radiation Treatment Affects Chromosome Testing in Uveal Melanoma, Investigative Ophthalmology & Visual Science 56(10): 5956-5964.
- Bakker, R.M.; Vermeer, W.M.; Creutzberg, C.L.; Mens, J.W.M.; Nout, R.A. & Kuile, M.M. ter (2015), Qualitative Accounts of Patients’ Determinants of Vaginal Dilator Use after Pelvic Radiotherapy, Journal of Sexual Medicine 12.
- Amant, F.; Mirza, M.R.; Koskas, M. & Creutzberg, C.L. (2015), Cancer of the corpus uteri, International Journal of Gynecology and Obstetrics 131: S96-S104.
- Creutzberg, C.L.; Stiphout, R.G.P.M. van; Nout, R.A.; Lutgens, L.C.H.W.; Jurgenliemk-Schulz, I.M.; Jobsen, J.J.; Smit, V.T.H.B.M. & Lambin, P. (2015), Nomograms for Prediction of Outcome With or Without Adjuvant Radiation Therapy for Patients With Endometrial Cancer: A Pooled Analysis of PORTEC-1 and PORTEC-2 Trials, International Journal of Radiation Oncology - Biology - Physics 91(3): 530-539.
- Nooij, L.S.; Ongkiehong, P.J.; Zwet, E.W. van; Bosse, T.; Creutzberg, C.L.; Gaarenstroom, K.N. & Poelgeest, M.I.E. van (2015), Groin surgery and risk of recurrence in lymph node positive patients with vulvar squamous cell carcinoma, Gynecologic Oncology 139(3): 458-464.
- Bakker, R.M.; Vermeer, W.M.; Creutzberg, C.L.; Mens, J.W.M.; Nout, R.A. & Kuile, M.M. ter (2015), Qualitative Accounts of Patients' Determinants of Vaginal Dilator Use after Pelvic Radiotherapy, Journal of Sexual Medicine 12(3): 764-773.
- Vermeer, W.M.; Bakker, R.M.; Stiggelbout, A.M.; Creutzberg, C.L.; Kenter, G.G. & Kuile, M.M. ter (2015), Psychosexual support for gynecological cancer survivors: professionals' current practices and need for assistance, Supportive Care in Cancer 23(3): 831-839.
- Colombo, N.; Creutzberg, C.; Amant, F.; Bosse, T.; Gonzalez-Martin, A.; Ledermann, J.; Marth, C.; Nout, R.; Querleu, D.; Mirza, M.R.; Sessa, C. & ESMO-ESGO-ESTRO Endometrial (2015), ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up, Radiotherapy and Oncology 117(3): 559-581.
- Boer, S.M. de; Nout, R.A.; Jurgenliemk-Schulz, I.M.; Jobsen, J.J.; Lutgens, L.C.H.W.; Steen-Banasik, E.M. van der; Mens, J.W.M.; Slot, A.; Kroese, M.C.S.; Oerlemans, S.; Putter, H.; Verhoeven-Adema, K.W.; Nijman, H.W. & Creutzberg, C.L. (2015), Long-Term Impact of Endometrial Cancer Diagnosis and Treatment on Health-Related Quality of Life and Cancer Survivorship: Results From the Randomized PORTEC-2 Trial, International Journal of Radiation Oncology - Biology - Physics 93(4): 797-809.
- Dogrusoz, M.; Kroes, W.G.M.; Duinen, S. van; Creutzberg, C.L.; Versluis, M.; Bleeker, J.C.; Marinkovic, M.; Luyten, G.P.M. & Jager, M.J. (2015), Irradiation enhances chromosomal aberrations in uveal melanoma, Investigative Ophthalmology & Visual Science 56(7).
- Wiltink, L.M.; Nout, R.A.; Fiocco, M.; Kranenbarg, E.M.K.; Jurgenliemk-Schulz, I.M.; Jobsen, J.J.; Nagtegaal, I.D.; Rutten, H.J.T.; Velde, C.J.H. van de; Creutzberg, C.L. & Marijnen, C.A.M. (2015), No Increased Risk of Second Cancer After Radiotherapy in Patients Treated for Rectal or Endometrial Cancer in the Randomized TME, PORTEC-1, and PORTEC-2 Trials, Journal of Clinical Oncology 33(15): 1640-+.
- Mitra, D.; Nout, R.; Catalano, P.J.; Creutzberg, C.; Cimbak, N.; Lee, L. & Viswanathan, A.N. (2015), Rectal bleeding after radiation therapy for endometrial cancer, Radiotherapy and Oncology 115(2): 240-245.
- Church, D.N.; Stelloo, E.; Nout, R.A.; Valtcheva, N.; Depreeuw, J.; Haar, N. ter; Noske, A.; Amant, F.; Tomlinson, I.P.M.; Wild, P.J.; Lambrechts, D.; Jurgenliemk-Schulz, I.M.; Jobsen, J.J.; Smit, V.T.H.B.M.; Creutzberg, C.L. & Bosse, T. (2015), Prognostic Significance of POLE Proofreading Mutations in Endometrial Cancer, JNCI: Journal of the National Cancer Institute 107(1).
- Gool, I. van; Eggink, F.; Freeman-Mills, L.; Stelloo, E.; Marchi, E.; Palles, C.; Bruyn, M. de; Nout, R.; Kroon, C. de; Osse, M.; Klenerman, P.; Creutzberg, C.; Tomlinson, I.; Smit, V.; Nijman, H.; Bosse, T. & Church, D. (2015), POLE proofreading mutations elicit an anti-tumor immune response in endometrial cancer, European Journal of Cancer 51: S29-S29.
- Versluis, M.A.; Jong, R.A. de; Plat, A.; Bosse, T.; Smit, V.T.; Mackay, H.; Powell, M.; Leary, A.; Mileshkin, L.; Kitchener, H.C.; Crosbie, E.J.; Edmondson, R.J.; Creutzberg, C.L.; Hollema, H.; Daemen, T.; Bock, G.H. de & Nijman, H.W. (2015), Prediction model for regional or distant recurrence in endometrial cancer based on classical pathological and immunological parameters, British Journal of Cancer 113(5): 786-793.
- Bosse, T.; Peters, E.E.M.; Creutzberg, C.L.; Jurenliemk-Schulz, I.M.; Jobsen, J.J.; Mens, J.W.M.; Lutgens, L.C.H.W.; Steen-Banasik, E.M. van der; Smit, V.T.H.B.M. & Nout, R.A. (2015), Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer - A pooled analysis of PORTEC 1 and 2 trials, European Journal of Cancer 51(13): 1742-1750.
- Stelloo, E.; Bosse, T.; Nout, R.A.; MacKay, H.J.; Church, D.N.; Nijman, H.W.; Leary, A.; Edmondson, R.J.; Powell, M.E.; Crosbie, E.J.; Kitchener, H.C.; Mileshkin, L.; Pollock, P.M.; Smit, V.T. & Creutzberg, C.L. (2015), Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative, Modern Pathology 28(6): 836-844.
- Malak, S.; Oerlemans, S.; Efficace, F.; Bredart, A.; Kyriakou, C.; Daniels, L.; Creutzberg, C.; Cocks, K.; Sztankay, M.; Pallua, S.; Caocci, G.; Molica, S.; Chie, W. & Poll-Franse, L. van de (2015), CROSS-CULTURAL DEVELOPMENT OF FOUR EORTC QUESTIONNAIRES TO ASSESS QUALITY OF LIFE IN PATIENTS WITH HODGKIN LYMPHOMA, NON-HODGKIN LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKAEMIA, Haematologica 100: 149-149.
- Gool, I.C. van; Eggink, F.A.; Freeman-Mills, L.; Stelloo, E.; Marchi, E.; Bruyn, M. de; Palles, C.; Nout, R.A.; Kroon, C.D. de; Osse, E.M.; Klenerman, P.; Creutzberg, C.L.; Tomlinson, I.P.M.; Smit, V.T.H.B.M.; Nijman, H.W.; Bosse, T. & Church, D.N. (2015), POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer, Clinical Cancer Research 21(14): 3347-3355.
- Wiltink L.M., Nout R.A., Fiocco M., Meershoek-Klein Kranenbarg E., Jurgenliemk-Schulz I.M., Jobsen J.J., Nagtegaal I.D., Velde C.J.H. van de, Creutzberg C.L. & Marijnen C.A.M. (2014), Second Cancers in Patients Treated With Surgery and Radiation Therapy for Rectal or Endometrial Cancer in the Randomized TME, PORTEC-1, and PORTEC-2 Trials, International Journal of Radiation Oncology - Biology - Physics 90(1): S85-S86.
- Vermeer, W.M.; Bakker, R.M.; Stiggelbout, A.M.; Creutzberg, C.L.; Kenter, G.G. & Kuile, M.M. ter (2014), Psychosexual support for gynecological cancer survivors: professionals' current practices and need for assistance., Supportive Care in Cancer.
- Bakker, R.M.; Kuile, M.M. ter; Vermeer, W.M.; Nout, R.A.; Mens, J.W.M.; Doorn, L.C. van; Kroon, C.D. de; Hompus, W.C.P.; Braat, C. & Creutzberg, C.L. (2014), Sexual rehabilitation after pelvic radiotherapy and vaginal dilator use: consensus using the Delphi method., International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.
- LR S, van der Kaaij M, van Dorst E, C C, E H & CE K (2014), Sexual dysfunction and infertility as late effects of cancer treatment., EJC supplements : EJC : official journal of EORTC, European Organization for Research and Treatment of Cancer ... [et al.].
- Mitra, D.; Nout, R.; Creutzberg, C.; Lee, L.J.; Cimbak, N.C. & Viswanathan, A.N. (2014), Does Adding Vaginal Brachytherapy (VB) to External Beam (EB) Increase Rectal Bleeding?: Comparing Results of Combined EB plus VB to the PORTEC-2 Data for EB Alone and VB Alone, International Journal of Radiation Oncology - Biology - Physics 90: S710-S711.
- Nickkho-Amiry, M.; Kaufmann, A.; Bosse, T.; Leary, A.; McKay, H.; Powell, M.; Mileshkin, L.; Creutzberg, C.L.; Kitchener, H.C.; Crosbie, E.J. & Edmondson, R.J. (2014), USE OF MOLECULAR MARKERS IMPROVES PROGNOSTIC STRATIFICATION IN HIGH RISK ENDOMETRIAL CANCER: A TRANSPORTEC COLLABORATIVE STUDY, International Journal of Gynecological Cancer 24(9): 1501-1502.
- Kunneman, M.; Pieterse, A.H.; Stiggelbout, A.M.; Nout, R.A.; Kamps, M.; Lutgens, L.C.H.W.; Paulissen, J.; Mattheussens, O.J.A.; Kruitwagen, R.F.P.M. & Creutzberg, C.L. (2014), Treatment preferences and involvement in treatment decision making of patients with endometrial cancer and clinicians, British Journal of Cancer 111(4): 674-679.
- Bakker, R.M.; Kuile, M.M. ter; Vermeer, W.M.; Nout, R.A.; Mens, J.W.M.; Doorn, L.C. van; Kroon, C.D. de; Hompus, W.C.P.; Braat, C. & Creutzberg, C.L. (2014), Sexual Rehabilitation After Pelvic Radiotherapy and Vaginal Dilator Use Consensus Using the Delphi Method, International Journal of Gynecological Cancer 24(8): 1499-1506.
- Stelloo, E.; Nout, R.A.; Naves, L.C.L.M.; Haar, N.T. ter; Creutzberg, C.L.; Smit, V.T.H.B.M. & Bosse, T. (2014), High concordance of molecular tumor alterations between pre-operative curettage and hysterectomy specimens in patients with endometrial carcinoma, Gynecologic Oncology 133(2): 197-204.
- Bosse, T.; Nout, R.A.; Stelloo, E.; Dreef, E.; Nijman, H.W.; Jurgenliemk-Schulz, I.M.; Jobsen, J.J.; Creutzberg, C.L. & Smit, V.T.H.B.M. (2014), L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: Pooled PORTEC trial results, European Journal of Cancer 50(15): 2602-2610.
- Arnold, M.; Liu, L.F.; Kenter, G.G.; Creutzberg, C.L.; Coebergh, J.W. & Soerjomataram, I. (2014), Second primary cancers in survivors of cervical cancer in the Netherlands: Implications for prevention and surveillance, Radiotherapy and Oncology 111(3): 374-381.
- Daniels, L.A.; Krol, A.D.G.; Graaf, M.A. de; Scholte, A.J.H.A.; van't Veer, M.B.; Putter, H.; Roos, A. de; Schalij, M.J. & Creutzberg, C.L. (2014), Screening for coronary artery disease after mediastinal irradiation in Hodgkin lymphoma survivors: phase II study of indication and acceptance, Annals of Oncology 25(6): 1198-1203.
- Rijkmans, E.C.; Nout, R.A.; Rutten, I.H.H.M.; Ketelaars, M.; Neelis, K.J.; Laman, M.S.; Coen, V.L.M.A.; Gaarenstroom, K.N.; Kroep, J.R. & Creutzberg, C.L. (2014), Improved survival of patients with cervical cancer treated with image-guided brachytherapy compared with conventional brachytherapy, Gynecologic Oncology 135(2): 231-238.
- Nout, R.A.; Peters, E.E.M.; Jurgenlienik-Schulz, I.M.; Jobsen, J.J.; Mens, J.W.M.; Stelloo, E.; Smit, V.T.H.; Bosse, T. & Creutzberg, C.L. (2014), Quantification of LVSI Improves Its Strength as Prognostic Factor for Recurrence in Stage I Endometrial Cancer Patients Treated in the PORTEC Trials, International Journal of Radiation Oncology - Biology - Physics 90: S110-S111.
- Church, D.; Stelloo, E.; Nout, R.A.; Valtcheva, N.; Depreeuw, J.; Haar, N. ter; Amant, F.; Tomlinson, I.P.M.; Wild, P.; Smit, V.; Creutzberg, C.L. & Bosse, T. (2014), PROGNOSTIC SIGNIFICANCE OF POLE EXONUCLEASE DOMAIN MUTATION IN EARLY STAGE ENDOMETRIAL CANCER, International Journal of Gynecological Cancer 24(9): 1601-1602.
- Blinman, P.; Mileshkin, L.; Khaw, P.; Goss, G.; Johnson, C.; Capp, A.; Brooks, S.; Wain, G.; Kolodzeij, I.; Veillard, A.S.; Creutzberg, C. & Stockler, M. (2014), PREFERENCES FOR ADJUVANT CHEMOTHERAPY IN AN ANZGOG SUBSTUDY OF THE PORTEC-3 INTERGROUP RANDOMIZED CONTROLLED TRIAL OF ADJUVANT CHEMOTHERAPY IN HIGH RISK ENDOMETRIAL CANCER.
- Bosse, T.; Nout, R.A.; Stelloo, E.; Mackay, H.J.; Church, D.; Powell, M.; Leary, A.; Mileshkin, L.; Kitchener, H.; Smit, V. & Creutzberg, C.L. (2014), MOLECULAR PROFILING OF HIGH-RISK ENDOMETRIAL CANCER; A TRANSPORTEC PILOT STUDY, International Journal of Gynecological Cancer 24(9): 1503-1504.
- Daniels, L.A.; Krol, S.D.G.; Graaf, M.A. de; Scholte, A.J.H.A.; van't Veer, M.B.; Putter, H.; Roos, A. de; Schalij, M.J.; Poll-Franse, L.V. van de & Creutzberg, C.L. (2014), Impact of Cardiovascular Counseling and Screening in Hodgkin Lymphoma Survivors, International Journal of Radiation Oncology - Biology - Physics 90(1): 164-171.
- Sagae, S.; Susumu, N.; Viswanathan, A.N.; Aoki, D.; Backes, F.J.; Provencher, D.M.; Vaughan, M.; Creutzberg, C.L.; Kurzeder, C.; Kristensen, G.; Lee, C.; Kurtz, J.E.; Glasspool, R.M. & Small, W. (2014), Gynecologic Cancer InterGroup (GCIG) Consensus Review for Uterine Serous Carcinoma, International Journal of Gynecological Cancer 24(9): S83-S89.
- Berton-Rigaud, D.; Devouassoux-Shisheboran, M.; Ledermann, J.A.; Leitao, M.M.; Powell, M.A.; Poveda, A.; Beale, P.; Glasspool, R.M.; Creutzberg, C.L.; Harter, P.; Kim, J.W.; Reed, N.S. & Ray-Coquard, I. (2014), Gynecologic Cancer InterGroup (GCIG) Consensus Review for Uterine and Ovarian Carcinosarcoma, International Journal of Gynecological Cancer 24(9): S55-S60.
- Genestie, C.; Adam, J.; Bosse, T.; Edmonson, R.; Kitchener, H.; Pollock, P.; Mileshkin, L.; Mackay, H.; Creutzberg, C. & Leary, A. (2014), EVALUATION OF DNA REPAIR BIOMARKERS IN HIGH-RISK ENDOMETRIAL CANCER: A TRANSPORTEC PILOT STUDY, International Journal of Gynecological Cancer 24(9): 1010-1011.
- Small, W.; Bosch, W.R.; Strauss, J.B.; Albuquerque, K.; Beriwal, S.; Creutzberg, C.L.; Eifel, P.J.; Erickson, B.A.; Fyles, T.W.; Jhingran, A.; Klopp, A.H.; Kunos, C.; Mell, L.K.; Powell, M.; Viswanathan, A.N.; Yashar, C.M. & Gaffney, D. (2014), Consensus Guidelines for Delineation of Clinical Target Volume for Intensity-Modulated Pelvic Radiation Therapy in Postoperative Treatment of Endometrial and Cervical Cancer- An Update, International Journal of Radiation Oncology - Biology - Physics 90: S109-S109.
- Bakker, R.M.; Kuile, M.M. ter; Vermeer, W.M.; Nout, R.A.; Mens, J.W.M.; Doorn, L.C. van; Kroon, C.D. de; Hompus, W.C.P.; Braat, C. & Creutzberg, C.L. (2014), Sexual Rehabilitation After Pelvic Radiotherapy and Vaginal Dilator Use Consensus Using the Delphi Method, International Journal of Gynecological Cancer 24(8).
- Daniels, L.A.; Oerlemans, S.; Krol, A.D.G.; Creutzberg, C.L. & Poll-Franse, L.V. van de (2014), Chronic fatigue in Hodgkin lymphoma survivors and associations with anxiety, depression and comorbidity, British Journal of Cancer 110(4): 868-874.
- Wiltink, L.M.; Nout, R.A.; Fiocco, M.; Kranenbarg, E.M.K.; Jurgenliemk-Schulz, I.M.; Jobsen, J.J.; Nagtegaal, I.D.; Velde, C.J.H. van de; Creutzberg, C.L. & Marijnen, C.A.M. (2014), Second Cancers in Patients Treated With Surgery and Radiation Therapy for Rectal or Endometrial Cancer in the Randomized TME, PORTEC-1, and PORTEC-2 Trials, International Journal of Radiation Oncology - Biology - Physics 90: S85-S86.
- Pieterse, Q.D.; Kenter, G.G.; Maas, C.P.; Kroon, C.D. de; Creutzberg, C.L.; Trimbos, J.B.M.Z. & Kuile, M.M. ter (2013), Self-reported sexual, bowel and bladder function in cervical cancer patients following different treatment modalities: longitudinal prospective cohort study., International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.
- Creutzberg, C.L.; Kitchener, H.C.; Birrer, M.J.; Landoni, F.; Lu, K.H.; Powell, M.; Aghajanian, C.; Edmondson, R.; Goodfellow, P.J.; Quinn, M.; Salvesen, H.B.; Thomas, G. & Second GCIG Endometrial Canc (2013), Gynecologic Cancer InterGroup (GCIG) Endometrial Cancer Clinical Trials Planning Meeting: taking endometrial cancer trials into the translational era., International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.
- Creutzberg, C.L.; Kitchener, H.C.; Birrer, M.J.; Landoni, F.; Lu, K.H.; Powell, M.; Aghajanian, C.; Edmondson, R.; Goodfellow, P.J.; Quinn, M.; Salvesen, H.B.; Thomas, G. & Second GCIG Endometrial Canc (2013), Gynecologic Cancer InterGroup (GCIG) Endometrial Cancer Clinical Trials Planning Meeting Taking Endometrial Cancer Trials Into the Translational Era, International Journal of Gynecological Cancer 23(8): 1528-1534.
- Stelloo, E.; Nout, R.A.; Naves, L.C.L.M.; Haar, N.T. ter; Creutzberg, C.L.; Smit, T.H.B.M. & Bosse, T. (2013), HIGH CORRELATION OF MOLECULAR TUMOR ALTERATIONS IN ENDOMETRIAL CURRETAGE AND HYSTERECTOMY-SPECIMENS IN PATIENTS WITH ENDOMETRIAL CARCINOMA, International Journal of Gynecological Cancer 23(8).
- Nout, R.; Boer, S. de; Putter, H.; Jurgenliemk-Schulz, I.; Jobsen, J.; Lutgens, L.; Steen-Banasik, E. van der; Mens, J.W.; Slot, A.; Stenfert-Kroese, M.; Verhoeven-Adema, K.; Stelloo, E.; Bosse, T.; Smit, V. & Creutzberg, C. (2013), Vaginal brachytherapy versus external beam pelvic radiotherapy for high-intermediate risk endometrial cancer: Long term results of the randomized PORTEC-2 trial, European Journal of Cancer 49: S714-S714.
- Daniels, L.A.; Krol, A.; Graaf, M.A. de; Scholte, A.J.H.A.; Putter, H.; Veer, M.B.V.T.; Roos, A. de; Schalij, M.J. & Creutzberg, C.L. (2013), Screening for coronary artery disease after mediastinal irradiation in Hodgkin lymphoma survivors, Journal of Clinical Oncology 31(15).
- Bosse, T.; Haar, N.T. ter; Seeber, L.M.; Diest, P.J. van; Hes, F.J.; Vasen, H.F.A.; Nout, R.A.; Creutzberg, C.L.; Morreau, H. & Smit, V.T.H.B.M. (2013), Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer, Modern Pathology 26(11): 1525-1535.
- Pieterse, Q.D.; Kenter, G.G.; Maas, C.P.; Kroon, C.D. de; Creutzberg, C.L.; Trimbos, J.B.M.Z. & Kuile, M.M. ter (2013), Self-Reported Sexual, Bowel and Bladder Function in Cervical Cancer Patients Following Different Treatment Modalities Longitudinal Prospective Cohort Study, International Journal of Gynecological Cancer 23(9): 1717-1725.
- Creutzberg, C.L.; Stiphout, R.G.P.M. van; Nout, R.A.; Lutgens, L.C.H.W.; Jurgenliemk-Schulz, I.M.; Jobsen, J.J.; Smit, V.T.H. & Lambin, P. (2013), Nomogram for prediction of outcome for patients with endometrium cancer: a pooled analysis of PORTEC-1 and PORTEC-2 trials, European Journal of Cancer 49: S726-S727.
- Felderhof, J.M.; Creutzberg, C.L.; Putter, H.; Nout, R.A.; Bovee, J.V.M.G.; Dijkstra, P.D.S.; Hartgrink, H.H. & Marijnen, C.A.M. (2013), Long-term clinical outcome of patients with soft tissue sarcomas treated with limb-sparing surgery and postoperative radiotherapy, Acta Oncologica 52(4): 745-752.
- Daniels, L.A.; Oerlemans, S.; Krol, A.D.G.; Poll-Franse, L.V. van de & Creutzberg, C.L. (2013), Persisting fatigue in Hodgkin lymphoma survivors: a systematic review, Annals of Hematology 92(8): 1023-1032.
- Daniels, L.A.; Krol, A.D.G.; Schaapveld, M.; Putter, H.; Jansen, P.M.; Marijt, E.W.A.; Leeuwen, F.E. van & Creutzberg, C.L. (2013), Long-term risk of secondary skin cancers after radiation therapy for Hodgkin's lymphoma, Radiotherapy and Oncology 109(1): 140-145.
- Nout, R.A.; Bosse, T.; Creutzberg, C.L.; Jurgenliemk-Schulz, I.M.; Jobsen, J.J.; Lutgens, L.C.H.W.; Steen-Banasik, E.M. van der; Eijk, R. van; Haar, N.T. ter & Smit, V.T.H.B.M. (2012), Improved risk assessment of endometrial cancer by combined analysis of MSI, PI3K-AKT, Wnt/β-catenin and P53 pathway activation., Gynecologic Oncology.
- Oerlemans, S.; Husson, O.; Mols, F.; Poortmans, P.; Roerdink, H.; Daniels, L.A.; Creutzberg, C.L. & Poll-Franse, L.V. van de (2012), Perceived information provision and satisfaction among lymphoma and multiple myeloma survivors--results from a Dutch population-based study., Annals of Hematology.
- Pieterse, Q.; Kenter, G.; Kroon, C. de; Creutzberg, C.; Trimbos, B. & Kuile, M. ter (2012), BLADDER, ANORECTAL AND SEXUAL FUNCTION AFTER NERVE-SPARING RADICAL HYSTERECTOMY FOR THE TREATMENT OF CERVICAL CANCER; A LONGITUDINAL PROSPECTIVE COHORT STUDY.
- Viswanathan, A.N.; Creutzberg, C.L.; Craighead, P.; McCormack, M.; Toita, T.; Narayan, K.; Reed, N.; Long, H.; Kim, H.J.; Marth, C.; Lindegaard, J.C.; Cerrotta, A.; Small, W. & Trimble, E. (2012), INTERNATIONAL BRACHYTHERAPY PRACTICE PATTERNS: A SURVEY OF THE GYNECOLOGIC CANCER INTERGROUP (GCIG), International Journal of Radiation Oncology - Biology - Physics 82(1): 250-255.
- Amant, F.; Mirza, M.R. & Creutzberg, C.L. (2012), Cancer of the corpus uteri, International Journal of Gynecology and Obstetrics 119: S110-S117.
- Nout, R.A.; Putter, H.; Jurgenliemk-Schulz, I.M.; Jobsen, J.J.; Lutgens, L.C.H.W.; Steen-Banasik, E.M. van der; Mens, J.W.M.; Slot, A.; Kroese, M.C.S.; Nijman, H.W.; Poll-Franse, L.V. van de & Creutzberg, C.L. (2012), Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data, European Journal of Cancer 48(11): 1638-1648.
- Nout, R.A.; Bosse, T.; Creutzberg, C.L.; Jurgenliemk-Schulz, I.M.; Jobsen, J.J.; Lutgens, L.C.H.W.; Steen-Banasik, E.M. van der; Eijk, R. van; Haar, N.T. ter & Smit, V.T.H.B.M. (2012), Improved risk assessment of endometrial cancer by combined analysis of MSI, PI3K-AKT, Wnt/beta-catenin and P53 pathway activation, Gynecologic Oncology 126(3): 466-473.
- Oerlemans, S.; Husson, O.; Mols, F.; Poortmans, P.; Roerdink, H.; Daniels, L.A.; Creutzberg, C.L. & Poll-Franse, L.V. van de (2012), Perceived information provision and satisfaction among lymphoma and multiple myeloma survivors-results from a Dutch population-based study, Annals of Hematology 91(10): 1587-1595.
- Razzaq, L.; Keunen, J.E.E.; Schalij-Delfos, N.E.; Creutzberg, C.L.; Ketelaars, M. & Keizer, R.J.W. de (2012), Ruthenium plaque radiation therapy for iris and iridociliary melanomas.
- Nout, R.A.; Bosse, T.; Creutzberg, C.L.; Jurgenliemk-Schulz, I.M.; Jobsen, J.J.; Lutgens, L.C.H.W.; Steen-Banasik, E.M. van der; Eijk, R. van; Haar, N.T. ter & Smit, V.T.H.B.M. (2012), Improved risk assessment of endometrial cancer by combined analysis of MSI, PI3K-AKT, Wnt/β-catenin and P53 pathway activation., Gynecologic Oncology 126(3): 466-73.
- Creutzberg, C. (2011), ADJUVANT TREATMENT OF ENDOMETRIAL CANCER: CURRENT EVIDENCE AND ONGOING TRIALS., Radiotherapy and Oncology 99: S227-S227.
- Nout, R.; Jurgenliemk-Schulz, I.M.; Laman, M.; Nomden, C.; Ketelaars, M.; Leeuw, A. de & Creutzberg, C. (2011), VAGINAL BRACHYTHERAPY WITH MRI GUIDANCE: TARGET VOLUME DEFINITION AND EFFECT OF BLADDER FILLING ON DOSE TO ORGANS AT RISK., Radiotherapy and Oncology 99: S118-S118.
- Coremans, I.; Wiggenraad, R.; Jong, M. de; Santvoort, J. van; Ages, D.; Putter, H.; Duinen, S. van; Natte, R.; Taphoorn, M.; Marijnen, C. & Creutzberg, C. (2011), PATTERNS OF RECURRENCE AND SURVIVAL IN 168 GLIOBLASTOMA PATIENTS AFTER TEMOZOLOMIDE BASED CHEMORADIATION, Radiotherapy and Oncology 99: S366-S367.
- Creutzberg, C.L. & Nout, R.A. (2011), The Role of Radiotherapy in Endometrial Cancer: Current Evidence and Trends, Current Oncology Reports 13(6): 472-478.
- Creutzberg, C.L.; Nout, R.A.; Lybeert, M.L.M.; Warlam-Rodenhuis, C.C.; Jobsen, J.J.; Mens, J.W.M.; Lutgens, L.C.H.W.; Pras, E.; Poll-Franse, L.V. van de; Putten, W.L.J. van & PORTEC Study Grp (2011), FIFTEEN-YEAR RADIOTHERAPY OUTCOMES OF THE RANDOMIZED PORTEC-1 TRIAL FOR ENDOMETRIAL CARCINOMA, International Journal of Radiation Oncology - Biology - Physics 81(4): E631-E638.
- Creutzberg, C.L.; Nout, R.A.; Lybeert, M.L.M.; Warlam-Rodenhuis, C.C.; Jobsen, J.J.; Mens, J.W.M.; Lutgens, L.C.H.W.; Pras, E.; Poll-Franse, L.V. van de; Putten, W.L.J. van & PORTEC Study Grp (2011), Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma., International Journal of Radiation Oncology - Biology - Physics 81(4): e631-8.
- Greimel, E.; Nordin, A.; Lanceley, A.; Creutzberg, C.L.; Poll-Franse, L.V. van de; Radisic, V.B.; Galalae, R.; Schmalz, C.; Barlow, E.; Jensen, P.T.; Waldenstrom, A.C.; Bergmark, K.; Chie, W.C.; Kuljanic, K.; Costantini, A.; Singer, S.; Koensgen, D.; Menon, U.; Daghofer, F. & EORTC Quality Life Grp (2011), Psychometric validation of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Endometrial Cancer Module (EORTC QLQ-EN24), European Journal of Cancer 47(2): 183-190.
- Nout, R.A. & Creutzberg, C.L. (2011), Point: Vaginal brachytherapy should be a standard adjuvant treatment for intermediate-risk endometrial cancer, Brachytherapy 10(1): 1-3.
- Nout, R.A.; Poll-Franse, L.V. van de; Lybeert, M.L.M.; Warlam-Rodenhuis, C.C.; Jobsen, J.J.; Mens, J.W.M.; Lutgens, L.C.H.W.; Pras, B.; Putten, W.L.J. van & Creutzberg, C.L. (2011), Long-Term Outcome and Quality of Life of Patients With Endometrial Carcinoma Treated With or Without Pelvic Radiotherapy in the Post Operative Radiation Therapy in Endometrial Carcinoma 1 (PORTEC-1) Trial, Journal of Clinical Oncology 29(13): 1692-1700.
- Nout, R.A.; Putter, H.; Jurgenliemk-Schulz, I.M.; Jobsen, J.J.; Lutgens, L.C.H.W.; Steen-Banasik, E.M. van der; Mens, J.W.M.; Slot, A.; Kroese, M.C.S.; Nijman, H.W.; Poll-Franse, L.V. van de & Creutzberg, C.L. (2011), Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data.
- Nout, R.A. & Creutzberg, C.L. (2011), Counterpoint: The role of adjuvant radiation in endometrial cancer. Inside, outside, or not at all? Rebuttal, Brachytherapy 10(1): 7-7.
- Lim, K.; Small, W.; Portelance, L.; Creutzberg, C.; Jurgenliemk-Schulz, I.M.; Mundt, A.; Mell, L.K.; Mayr, N.; Viswanathan, A.; Jhingran, A.; Erickson, B.; Santos, J. de los; Gaffney, D.; Yashar, C.; Beriwal, S.; Wolfson, A.; Taylor, A.; Bosch, W.; Naqa, I. el; Fyles, A. & Gyn IMRT Consortium (2011), CONSENSUS GUIDELINES FOR DELINEATION OF CLINICAL TARGET VOLUME FOR INTENSITY-MODULATED PELVIC RADIOTHERAPY FOR THE DEFINITIVE TREATMENT OF CERVIX CANCER, International Journal of Radiation Oncology - Biology - Physics 79(2): 348-355.
- Felderhof, J.M.; Creutzberg, C.L.; Putter, H.; Nout, R.A.; Bovee, J.V.M.G.; Dijkstra, P.D.S.; Harlgrink, H.H. & Marijnen, C.A.M. (2011), Limb-sparing Surgery and Radiotherapy for Soft Tissue Sarcomas of the Extremities, European Journal of Cancer 47: S667-S667.
- Creutzberg, C.L. (2010), Adjuvant chemotherapy for endometrial cancer: unproven., International Journal of Gynecological Cancer 20(11 Suppl 2): S60-3.
- Creutzberg, C.L. (2010), Adjuvant Chemotherapy for Endometrial Cancer Unproven, International Journal of Gynecological Cancer 20(7): 1105-1108.
- Creutzberg, C. (2010), ENDOMETRIAL CANCER: THE CHANGING ROLE OF RADIATION THERAPY, Radiotherapy and Oncology 96: S184-S185.
- Verschueren, K.M.S.; Creutzberg, C.L.; Schalij-Delfos, N.E.; Ketelaars, M.; Klijsen, F.L.L.; Haeseker, B.I.; Ligtenberg, S.M.B.; Keunen, J.E.E. & Marijnen, C.A.M. (2010), Long-term outcomes of eye-conserving treatment with Ruthenium(106) brachytherapy for choroidal melanoma., Radiotherapy and Oncology.
- Nout, R.; Putter, H.; Jurgenliemk-Schulz, M.; Jobsen, J.; Lutgens, L.; Steen-Banasik, E. van der; Mens, J.W.; Slot, A.; Nijman, H. & Creutzberg, C. (2010), LONG-TERM QUALITY OF LIFE AFTER RADIOTHERAPY FOR ENDOMETRIAL CANCER: RESULTS FROM THE RANDOMIZED PORTEC-2 TRIAL., Radiotherapy and Oncology 96: S145-S145.
- Nout, R.A.; Smit, V.T.H.B.M.; Putter, H.; Juergenliemk-Schulz, I.M.; Jobsen, J.J.; Lutgens, L.C.H.W.; Steen-Banasik, E.M. van der; Mens, J.W.M.; Slot, A.; Kroese, M.C.S.; Bunningen, B.N.F.M. van; Ansink, A.C.; Putten, W.L.J. van; Creutzberg, C.L. & PORTEC Study Grp (2010), Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial., Lancet (London, England).
- Razzaq, L.; Keunen, J.E.E.; Schalij-Delfos, N.; Jager, M.J.; Creutzberg, C.L. & Keizer, R.J.W. de (2010), Ruthenium Plaque Radiation Therapy for Iris and Iridociliary Melanomas and Its Complications, Investigative Ophthalmology & Visual Science 51(13).
- Nout, R.A.; Smit, V.T.H.B.M.; Putter, H.; Juergenliemk-Schulz, I.M.; Jobsen, J.J.; Lutgens, L.C.H.W.; Steen-Banasik, E.M. van der; Mens, J.W.M.; Slot, A.; Kroese, M.C.S.; Bunningen, B.N.F.M. van; Ansink, A.C.; Putten, W.L.J. van; Creutzberg, C.L. & PORTEC Study Grp (2010), Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial, Lancet 375(9717): 816-823.
- Lim, K.; Fyles, A.; Portelance, L.; Creutzberg, C.; Jurgenliemk-Schulz, I.M.; Viswanathan, A.; Erickson, B.; Bosch, W.; Naqa, I. el & Varia, M. (2010), Variability in Clinical Target Volume Delineation for Intensity Modulated Radiotherapy in Three Challenging Cervix Cancer Scenarios, International Journal of Radiation Oncology - Biology - Physics 78(3): S121-S122.
- Creutzberg, C.L. (2010), Adjuvant Chemotherapy for Endometrial Cancer Unproven, International Journal of Gynecological Cancer 20: S60S63.
- Verschueren, K.M.S.; Creutzberg, C.L.; Schalij-Delfos, N.E.; Ketelaars, M.; Klijsen, F.L.L.; Haeseker, B.I.; Ligtenberg, S.M.B.; Keunen, J.E.E. & Marijnen, C.A.M. (2010), Long-term outcomes of eye-conserving treatment with Ruthenium(106) brachytherapy for choroidal melanoma, Radiotherapy and Oncology 95(3): 332-338.
- Hezewijk, M. van; Creutzberg, C.L.; Putter, H.; Chin, A.; Schneider, I.; Hoogeveen, M.; Willemze, R. & Marijnen, C.A.M. (2010), Efficacy of a hypofractionated schedule in electron beam radiotherapy for epithelial skin cancer: Analysis of 434 cases, Radiotherapy and Oncology 95(2): 245-249.
- Razzaq, L.; Keunen, J.E.E.; Schalij-Delfos, N.E.; Creutzberg, C.L.; Ketelaars, M. & Keizer, R.J.W. de (2010), Ruthenium plaque radiation therapy for iris and iridociliary melanomas.
- Vergote, I.; Pujade-Lauraine, E.; Pignata, S.; Kristensen, G.B.; Ledermann, J.; Casado, A.; Sehouli, J.; Mirza, M.; Fossati, R.; Marth, C.; Creutzberg, C.; Campo, J. del; Siddiqui, N.; Calvert, P.; Bamias, A.; Tulunay, G.; Zee, A.G.J. van der; Bois, A. du & European Network Gynaecological (2010), European Network of Gynaecological Oncological Trial Groups' Requirements for Trials Between Academic Groups and Pharmaceutical Companies, International Journal of Gynecological Cancer 20(3): 476-478.
- Poll-Franse, L.V. van de; Mols, F.; Gundy, C.M.; Creutzberg, C.L.; Nout, R.A.; Verdonck-de Leeuw, I.M.; Taphoorn, M.J. & Aaronson, N.K. (2010), Normative data for the EORTC QLQ-C30 and EORTC-sexuality items in the general Dutch population.
- Lim, K.; Fyles, A.; Portelance, L.; Creutzberg, C.; Jurgenliemk-Schulz, I.M.; Viswanathan, A.; Erickson, B.; Bosch, W.; Naqa, I. el & Varia, M. (2010), Variability in Clinical Target Volume Delineation for Intensity Modulated Radiotherapy in Three Challenging Cervix Cancer Scenarios, International Journal of Radiation Oncology - Biology - Physics 78(3): S121S122.
- Kitchener, H.C.; Trimble, E.L. & Endometrial Canc Working Grp Gynec (2009), Endometrial cancer state of the science meeting., International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.
- Nout RA, Putter H, Jurgenliemk-Schulz IM, Jobsen JJ, Lutgens LCHW, van der Steen-Banasik EM, Mens JWM, Slot A, Kroese MCS & van Bunningen BNFM (2009), Quality of Life After Pelvic Radiotherapy or Vaginal Brachytherapy for Endometrial Cancer: First Results of the Randomized PORTEC-2 Trial, Journal of Clinical Oncology 27(21): 3547-3556.
- Creutzberg CL, Nout RA, van de Poll-Franse VL, Lybeert MLM, Warlam-Rodenhuis CC, Jobsen JJ, Mens JWM, Lutgens LCHW, Pras E & van Putten WLJ (2009), Long-term Outcome of the Randomized PORTEC-1 Trial and Quality of Life of the Endometrial Cancer Survivors, International Journal of Radiation Oncology - Biology - Physics 75(3): S146S147.
- Fyles AW, Lim K, Small W, Portelance L, Gaffney D, Erickson B, de los Santos J, Ishikura S, Creutzberg C & Bosch W (2009), Variability in Delineation of Clinical Target Volumes for Cervix Cancer Intensity-modulated Pelvic Radiotherapy, International Journal of Radiation Oncology - Biology - Physics 75(3): S83S84.
- Nout RA, Smit VTHB, Putter H, Jurgenliemk-Schulz IM, Jobsen JJ, Lutgens LCHW, van der Steen-Banasik EM, Mens JM, Slot A & Creutzberg CL (2009), Vaginal Brachytherapy vs. External Beam Radiotherapy for High-intermediate Risk Endometrial Cancer: Results of the Randomized PORTEC-2 Trial after Central Pathology Review, International Journal of Radiation Oncology - Biology - Physics 75(3): S87S87.
- Nout RA, Putter H, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, Mens JW, Slot A, Stenfert Kroese MC, van Bunningen BN, Smit VT, Nijman HW, van den Tol PP & Creutzberg CL (2009), Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial., Journal of Clinical Oncology 27(21): 3547-56.
- Franckena M, Lutgens LC, Koper PC, Kleynen CE, van der Steen-Banasik EM, Jobsen JJ, Leer JW, Creutzberg CL, Dielwart MF & van Norden Y (2009), RADIOTHERAPY AND HYPERTHERMIA FOR TREATMENT OF PRIMARY LOCALLY ADVANCED CERVIX CANCER: RESULTS IN 378 PATIENTS, International Journal of Radiation Oncology - Biology - Physics 73(1): 242-250.
- van Hezewijk M, Creutzberg CL, Putter H, Chin A, Willemze R & Marijnen CAM (2009), Efficacy of a hypofractionated schedule in electron beam radiotherapy for epithelial skin cancer: analysis of 434 cases, EJC Supplements 7(2): 584-584.
- Nout, R.; Putter, H.; Jurgenliemk-Schulz, I.; Jobsen, J.; Lutgens, L.; Steen-Banasik, E. van der; Mens, J.W.; Slot, A.; Kroese, M.S.; Bunningen, B. van; Smit, V.; Tol, P. van den & Creutzberg, C. (2008), VAGINAL BRACHYTHERAPY VERSUS EXTERNAL BEAM PELVIC RADIOTHERAPY FOR HIGH-INTERMEDIATE RISK ENDOMETRIAL CANCER: RESULTS OF THE RANDOMIZED PORTEC-2 TRIAL., Radiotherapy and Oncology 88: S19-S19.
- Creutzberg, C. (2008), RADIOTHERAPY FOR ENDOMETRIAL CANCER: CURRENT EVIDENCE AND TRENDS, Radiotherapy and Oncology 88: S55-S55.
- Small W, Mell LK, Anderson P, Creutzberg C, De Los Santos J, Gaffney D, Jhingran A, Portelance L, Schefter T, Iyer R, Varia M, Winter K & Mundt AJ (2008), Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer, International Journal of Radiation Oncology - Biology - Physics 71(2).
- Verschueren KMS, Schalij NE, Creutzberg CL, Ketelaars M, Klijssen FLL, Haeseker BI, Ligtenberg SMB & Marijnen CAM (2007), Long-term outcome of 403 patients treated with ruthenium brachytherapy for choroidal melanoma, EJC Supplements 5(4).
- Nout RA, Putter H, Schuitz IM, Jobsen JJ, Lutgens LCHM, van der Steen-Banasik EM, Mens JW, Slot A, Smit VT & Creutzberg CL (2007), Quality of life after radiotherapy for endometrial cancer: first results from the randomized PORTEC-2 trial, EJC Supplements 5(4).
- Scholten, A.N.; Aliredjo, R.; Creutzberg, C.L. & Smit, V.T.H.B.M. (2006), Combined E-cadherin, alpha-catenin, and beta-catenin expression is a favorable prognostic factor in endometrial carcinoma., International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.
- Kleijn WC, Ogoshi K, Yamaoka K, Shigehisa T, Takeda Y, Creutzberg CL, Nortier JW & Kaptein AA (2006), Conceptual equivalence and health-related quality of life: an exploratory study in Japanese and Dutch cancer patients., Quality of Life Research 15(6): 1091-101.
- Scholten AN, Aliredjo R, Creutzberg CL & Smit VT (2006), Combined E-cadherin, alpha-catenin, and beta-catenin expression is a favorable prognostic factor in endometrial carcinoma., International Journal of Gynecological Cancer 16(3): 1379-85.
- Kleijn WC, Ogoshi K, Yamaoka K, Shigehisa T, Takeda Y, Creutzberg CL, Nortier JWR & Kaptein AA (2006), Conceptual equivalence and health-related quality of life: an exploratory study in Japanese and Dutch cancer patients, Quality of Life Research 15(6).
- Pieterse QD, Trimbos JBMZ, Dijkman A, Creutzberg CL, Gaarenstroom KN, Peters AAW & Kenter GG (2006), Postoperative radiation therapy improves prognosis in patients with adverse risk factors in localized, early-stage cervical cancer: a retrospective comparative study, International Journal of Gynecological Cancer 16(3).
- Scholten AN, Aliredjo R, Creutzberg CL & Smit VTHBM (2006), Combined E-cadherin, alpha-catenin, and beta-catenin expression is a favorable prognostic factor in endometrial carcinoma, International Journal of Gynecological Cancer 16(3).
- Pieterse QD, Trimbos JB, Dijkman A, Creutzberg CL, Gaarenstroom KN, Peters AA & Kenter GG (2006), Postoperative radiation therapy improves prognosis in patients with adverse risk factors in localized, early-stage cervical cancer: a retrospective comparative study., International Journal of Gynecological Cancer 16(3): 1112-8.
- Scholten AN, van Putten WLJ, Beerman H, Smit VTHBM, Koper PCM, Lybeert MLM, Jobsen JJ, Warlam-Rodenhuis CC, De Winter KAJ, Lutgens LCHW, van Lent M & Creutzberg CL (2005), Postoperative radiotherapy for stage 1 endometrial carcinoma: Long-term outcome of the randomized PORTEC trial with central pathology review, International Journal of Radiation Oncology - Biology - Physics 63(3).
- Scholten AN, van Putten WL, Beerman H, Smit VT, Koper PC, Lybeert ML, Jobsen JJ, Wárlám-Rodenhuis CC, De Winter KA, Lutgens LC, van Lent M, Creutzberg CL & (2005), Postoperative radiotherapy for Stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review., International Journal of Radiation Oncology - Biology - Physics 63(3): 834-8.
- Creutzberg CL (2005), Lymphadenectomy in apparent early-stage endometrial carcinoma: Do numbers count?, Journal of Clinical Oncology 23(16).
- Mell L, Fyles A, Small W, Creutzberg C, Jhingran A, Arcangeli G, Varia M, Hatano K, De Los Santos J, Barillot I, Roeske J & Mundt A (2004), Adjuvant intensity modulated pelvic radiation therapy in gynecologic malignancies: Survey of the Gynecologic IMRT Working Group, International Journal of Radiation Oncology - Biology - Physics 60(1): S215S216.
- Creutzberg CL (2004), Survival after relapse in patients with endometrial cancer: results from a randomized trial - Response to the letter to the editor by Pijnenborg et al., Gynecologic Oncology 92(1).
- Scholten AN, Smit VTHBM, Beerman H, van Putten WLJ & Creutzberg CL (2004), Prognostic significance and interobserver variability of histologic grading systems for endometrial carcinoma, Cancer 100(4).
- Scholten AN, Smit VT, Beerman H, van Putten WL & Creutzberg CL (2004), Prognostic significance and interobserver variability of histologic grading systems for endometrial carcinoma., Cancer 100(4): 764-72.
- Creutzberg CL (2004), GOG-99: ending the controversy regarding pelvic radiotherapy for endometrial carcinoma?, Gynecologic Oncology 92(3).
- Seynaeve C, Verhoog LC, van de Bosch LMC, van Geel AN, Menke-Pluymers M, Meijers-Heijboer EJ, van den Ouweland AMW, Wagner A, Creutzberg CL, Niermeijer MF, Klijn JGM & Brekelmans CTM (2004), Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-conserving therapy, European Journal of Cancer 40(8).
- Creutzberg CL, van Putten WLJ, Warlam-Rodenhuis CC, van den Bergh ACM, De Winter KAJ, Koper PCM, Lybeert MLM, Slot A, Lutgens LCHW, Kroese MCS, Beerman H & van Lent M (2004), Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: The postoperative radiation therapy in endometrial carcinoma trial, Journal of Clinical Oncology 22(7).
- Scholten AN, Creutzberg CL, van den Broek LJCM, Noordijk EM & Smit VTHBM (2003), Nuclear beta-catenin is a molecular feature of type 1 endometrial carcinoma, Journal of Pathology 201(3).
- Creutzberg CL, van Putten WLJ, Koper PC, Lybeert MLM, Jobsen JJ, Warlam-Rodenhuis CC, De Winter KAJ, Lutgens LCHW, van den Bergh ACM, van der Steen-Banasik E, Beerman H & van Lent M (2003), Survival after relapse in patients with endometrial cancer: results from a randomized trial, Gynecologic Oncology 89(2).
- Davelaar J, Jobse MW, Hendriks EA, Creutzberg CL, Reiber JC & Stoel BC (2003), A new algorithm to register portal to planning images in radiotherapy and a validation using prostate treatments, Radiotherapy and Oncology 68.
- Scholten AN, Creutzberg CL, van den Broek LJ, Noordijk EM & Smit VT (2003), Nuclear beta-catenin is a molecular feature of type I endometrial carcinoma., Journal of Pathology 201(3): 460-5.
- Scholten AN, Creutzberg CL, Noordijk EM & Smit VT (2002), Long-term outcome in endometrial carcinoma favors a two- instead of a three-tiered grading system., International Journal of Radiation Oncology - Biology - Physics 52(4): 1067-74.
- Scholten AN, Creutzberg CL, Noordijk EM & Smit VTHBM (2002), Long-term outcome in endometrial carcinoma favors a two- instead of a three-tiered grading system, International Journal of Radiation Oncology - Biology - Physics 52(4).
- Noordijk EM & Creutzberg CL (2002), [Is there an indication for additional local irradiation in conserving treatment of breast cancer patients aged 60 and over?], Nederlands Tijdschrift voor Geneeskunde 146(9): 395-8.
- Olofsen-Van Acht, M.; Berg, H. van den; Quint, S.; Boer, H. de; Seven, M.; Koste, J.V. de; Creutzberg, C. & Visser, A. (2001), Reduction of irradiated small bowel volume and accurate patient positioning by use of a bellyboard device in pelvic radiotherapy of gynecological cancer patients, Radiotherapy and Oncology 59(1): 87-93.
- de Boer HCJ, de Koste JRV, Creutzberg CL, Visser AG, Levendag PC & Heijmen BJM (2001), Electronic portal image assisted reduction of systematic set-up errors in head and neck irradiation, Radiotherapy and Oncology 61(3).
- Creutzberg CL, van Putten WLJ, Koper PC, Lybeert MLM, Jobsen JJ, Warlam-Rodenhuis CC, De Winter KAJ, Lutgens LCHW, van den Bergh ACM, van der Steen-Banasik E, Beerman H & van Lent M (2001), The morbidity of treatment for patients with stage I endometrial cancer: Results from a randomized trial, International Journal of Radiation Oncology - Biology - Physics 51(5).
- Creutzberg, C.L.; Putten, W.L.J. van; Koper, P.C.M.; Lybeert, M.L.M.; Jobsen, J.J.; Warlam-Rodenhuis, C.C.; Winter, K.A.J. de; Lutgens, L.C.H.W.; Bergh, A.C.M. van den; Steen-Banasik, E. van de; Beerman, H.; Lent, M. van & PORTEC Study Grp (2000), Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial, The Lancet 355(9213): 1404-1411.
- Stroom, J.C.; Olofsen-van Acht, M.J.J.; Quint, S.; Seven, M.; Hoog, M. de; Creutzberg, C.L.; Boer, H.C.J. de & Visser, A.G. (2000), On-line set-up corrections during radiotherapy of patients with gynecologic tumors, International Journal of Radiation Oncology - Biology - Physics 46(2): 499-506.
- Creutzberg, C.L.; Putten, W.L.J. van; Koper, P.C.M.; Lybeert, M.L.M.; Jobsen, J.J.; Warlam-Rodenhuis, C.C.; Winter, K.A.J. de; Lutgens, L.C.H.W.; Bergh, A.C.M. van den; Steen-Banasik, E. van de; Beerman, H.; Lent, M. van & PORTEC Study Grp (2000), Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma., Lancet (London, England).
- Creutzberg, C. & Putten, W. van (2000), Treatment for patients with stage-1 endometrial carcinoma - Reply.
- Essers M, Eggen M, Binnekamp D, Creutzberg CL & Heijmen BJM (2000), Chest wall irradiation with MLC-shaped photon and electron fields, International Journal of Radiation Oncology - Biology - Physics 48(4).
- Creutzberg, C.L.; Althof, V.G.M.; deHoog, M.; Visser, A.G.; Huizenga, H.; Wijnmaalen, A. & Levendag, P.C. (1996), A quality control study of the accuracy of patient positioning in irradiation of pelvic fields, International Journal of Radiation Oncology - Biology - Physics 34(3): 697-708.
- Bel, A.; Vos, P.H.; Rodrigus, P.T.R.; Creutzberg, C.L.; Visser, A.G.; Stroom, J.C. & Lebesque, J.V. (1996), High-precision prostate cancer irradiation by clinical application of an offline patient setup verification procedure, using portal imaging, International Journal of Radiation Oncology - Biology - Physics 35(2): 321-332.
- CREUTZBERG, C.L.; ALTHOF, V.G.M.; HUIZENGA, H.; VISSER, A.G. & LEVENDAG, P.C. (1993), QUALITY ASSURANCE USING PORTAL IMAGING - THE ACCURACY OF PATIENT POSITIONING IN IRRADIATION OF BREAST-CANCER, International Journal of Radiation Oncology - Biology - Physics 25(3): 529-539.
- CREUTZBERG, C.L.; ALTHOF, V.G.M.; HUIZENGA, H.; VISSER, A.G. & LEVENDAG, P.C. (1993), Quality assurance using portal imaging: the accuracy of patient positioning in irradiation of breast cancer., International journal of radiation oncology, biology, physics.
- CREUTZBERG, C.L.; VISSER, A.G.; DEPORRE, P.M.Z.R.; MEERWALDT, J.H.; ALTHOF, V.G.M. & LEVENDAG, P.C. (1992), ACCURACY OF PATIENT POSITIONING IN MANTLE FIELD IRRADIATION, Radiotherapy and Oncology 23(4): 257-264.
- CL C, PP J & JW M (1989), [Visit to the emergency department: primary or secondary character?], Nederlands Tijdschrift voor Geneeskunde.
- Schelfhout LJ, Creutzberg CL, Hamming JF, Fleuren GJ, Smeenk D, Hermans J, van de Velde CJ & Goslings BM (1988), Multivariate analysis of survival in differentiated thyroid cancer: the prognostic significance of the age factor., European journal of cancer & clinical oncology 24(2): 331-7.
- SCHELFHOUT, L.J.D.M.; HAMMING, J.F.; CREUTZBERG, C.I.; FLEUREN, G.J.; HERMANS, J.; VANDEVELDE, C.J.H. & GOSLINGS, B.M. (1986), PROGNOSTIC FACTORS IN DIFFERENTIATED THYROID-CANCER, A MULTIVARIATE-ANALYSIS IN 190 CASES, Netherlands Journal of Medicine 29(9): 287-287.
- SCHELFHOUT, L.J.D.M.; HAMMING, J.F.; CREUTZBERG, C.M.; FLEUREN, G.J.; HERMANS, J.; VANDEVELDE, C.J.H. & GOSLINGS, B.M. (1986), PROGNOSTIC FACTORS IN DIFFERENTIATED THYROID-CANCER - A MULTIVARIATE-ANALYSIS IN 190 CASES, Annales d'Endocrinologie 47(6): 13-13.
- BROMBERG, J.E.C.; CREUTZBERG, C.L. & ATHERTON, D.J. (1985), SWEAT PRODUCTION IN CHILDRENS FEET, Clinical and Experimental Dermatology 10(3): 229-232.
- SCHELFHOUT, L.; CREUTZBERG, C. & GOSLINGS, B. (1984), DIFFERENTIATED THYROID-CARCINOMA - FOLLOW UP DATA ON 198 CASES, Annales d'Endocrinologie 45(1): 81-81.
- Bestuurslid
- Council member
- Lid concilium